



## Conference on ‘The future of animal products in the human diet: health and environmental concerns’

### Plenary Lecture 3 *n*-3 PUFA and health: fact, fiction and the future

## Very long-chain *n*-3 fatty acids and human health: fact, fiction and the future

P. C. Calder<sup>1,2</sup>

<sup>1</sup>Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, MP887  
Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK

<sup>2</sup>NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and  
University of Southampton, Southampton, UK

EPA and DHA appear to be the most important *n*-3 fatty acids, but roles for *n*-3 docosapentaenoic acid are now also emerging. Intakes of EPA and DHA are usually low, typically below those recommended. Increased intakes result in higher concentrations of EPA and DHA in blood lipids, cells and tissues. Increased content of EPA and DHA modifies the structure of cell membranes and the function of membrane proteins. EPA and DHA modulate the production of lipid mediators and through effects on cell signalling can alter the patterns of gene expression. Through these mechanisms, EPA and DHA alter cell and tissue responsiveness in a way that often results in more optimal conditions for growth, development and maintenance of health. DHA has vital roles in brain and eye development and function. EPA and DHA have a wide range of physiological roles, which are linked to certain health or clinical benefits, particularly related to CVD, cancer, inflammation and neurocognitive function. The benefits of EPA and DHA are evident throughout the life course. Future research will include better identification of the determinants of variation of responses to increased intake of EPA and DHA; more in-depth dose-response studies of the effects of EPA and DHA; clearer identification of the specific roles of EPA, docosapentaenoic acid and DHA; testing strategies to enhance delivery of *n*-3 fatty acids to the bloodstream; and exploration of sustainable alternatives to fish-derived very long-chain *n*-3 fatty acids.

**DHA: EPA: Fish oil: CVD: Cancer: Inflammation: Eicosanoids: Development: Brain**

#### ***n*-3 Fatty acids: structure, metabolic interrelationships, dietary sources and intakes**

*n*-3 Fatty acids are a family of PUFA<sup>(1)</sup>. They are defined by the position of the double bond closest to the methyl terminus of the hydrocarbon (acyl) chain. This is on carbon number three when counting the methyl carbon as

number one. EPA (20:5*n*-3) and DHA (22:6*n*-3) appear to be the most important *n*-3 fatty acids<sup>(2,3)</sup>, although roles for docosapentaenoic acid (DPA; 22:5*n*-3) are now also emerging<sup>(4,5)</sup>. Because of their long hydrocarbon chain, EPA, DPA and DHA are sometimes termed very long-chain *n*-3 fatty acids, in order to differentiate them from the 18-carbon plant-derived *n*-3 fatty acids

**Abbreviations:** ADHD, attention deficit hyperactivity disorder; ALA,  $\alpha$ -linolenic acid; ARA, arachidonic acid; DPA, docosapentaenoic acid; MI, myocardial infarction; RA, rheumatoid arthritis; RCT, randomised controlled trial; SDA, stearidonic acid.

**Corresponding author:** P. C. Calder, email [pcc@soton.ac.uk](mailto:pcc@soton.ac.uk)

like  $\alpha$ -linolenic acid (ALA; 18:3 $n$ -3) and stearidonic acid (SDA; 18:4 $n$ -3). In the present paper, the term 'very long-chain *n*-3 fatty acids' will be used to individually and collectively describe EPA, DPA and DHA.

EPA, DPA and DHA are metabolically related to one another, and there is a pathway by which EPA can be synthesised from the simpler plant-derived *n*-3 fatty acids (Fig. 1). The conversion of ALA to EPA involves three steps catalysed, in turn, by delta-6 desaturase, elongase 5 and delta-5 desaturase (Fig. 1). Further conversion of EPA to DHA, via DPA, occurs by a complex pathway (Fig. 1) involving chain elongation catalysed by elongase 5, a second chain elongation catalysed by elongase 2 or 5, desaturation by delta 6-desaturase, and then removal of two carbon atoms by limited  $\beta$ -oxidation in peroxisomes. The enzymes of *n*-3 fatty acid interconversion are shared with the analogous *n*-6 fatty acid biosynthetic pathway of conversion of linoleic acid (18:2 $n$ -6) to arachidonic acid (ARA; 20:4 $n$ -6) and beyond. The high intake of linoleic acid relative to ALA in many Western diets<sup>(6)</sup> favours linoleic acid conversion over that of ALA. This may be one explanation for the frequently reported low rate of conversion of ALA along this pathway<sup>(7,8)</sup>, although this rate can be influenced by several other factors including age<sup>(9)</sup>, sex<sup>(10-12)</sup>, hormones<sup>(13)</sup> and genetics<sup>(14)</sup>.

EPA and DHA are found in fairly high amounts in most seafood, especially in fatty fish (sometimes called oily fish), in the blubber and tissues of sea mammals like whales and seals, in supplements like fish oils, cod liver oil and krill oil, in some algal oils, and in a limited number of pharmaceutical grade preparations<sup>(15,16)</sup>. There is at least a 10-fold range in content of these fatty acids per serving of seafood, with fatty fish (e.g. mackerel, salmon, trout, herring, tuna and sardines) being the richest source (Table 1). Hence, intake of very long-chain *n*-3 fatty acids is strongly influenced by fish consumption. In most Western countries only a relatively small proportion of the population regularly consume fatty fish. For example, in the UK it is estimated that only 25% of the adult population are regular fatty fish consumers<sup>(17)</sup>. Consequently intakes of very long-chain *n*-3 fatty acids are low in much of the population and mean intakes of EPA + DHA among adults in many Western populations are considered to be about 0.1–0.3 g/d<sup>(17)</sup>. However, it is difficult to be precise about this figure for several reasons, as discussed elsewhere<sup>(3)</sup>. A series of Australian studies in adults and children provide probably the most accurate data on intake of very long-chain *n*-3 fatty acids. Data from over 10 000 Australian adults identified mean daily intakes of EPA, DPA and DHA as 56, 26 and 106 mg, respectively, to give a total very long-chain *n*-3 fatty acid intake of 189 mg/d<sup>(18)</sup>, consistent with the oft-quoted average intake of these fatty acids among Western adults. However, median intakes of EPA, DPA and DHA were found to be only 8, 6 and 15 mg/d, respectively<sup>(18)</sup>. The large differences between mean and median intakes reflect the skewed distribution of the intake data. A more recent study using an updated nutrient composition database produced mean daily intake data for EPA, DPA and DHA of 75, 71 and 100 mg, respectively, in




Fig. 1. The metabolic pathway of biosynthesis of EPA, docosapentaenoic acid and DHA.

Australian adults, giving a mean total very long-chain *n*-3 fatty acid intake of 246 mg/d<sup>(19)</sup>. Again, median intakes were lower, being about 50% of the mean. The data suggest that 50% of Australian adults consume less than about 120 mg of very long-chain *n*-3 fatty acids daily. There is no reason to think that average intakes would be higher than this in other Western countries, and in many they may be lower. Australian children and adolescents aged 2–16 years consumed a mean of 79 mg/d EPA + DPA + DHA, with a median intake of 29 mg/d<sup>(20)</sup>. Intakes increased with age and were much higher in fish eaters than non-fish eaters<sup>(20)</sup>.

The oil used in many *n*-3 fatty acid supplements is sourced from fish; as such this may be referred to as fish oil. Other, non-fish, sources of oil such as krill and algae are also used in supplements. These different oils differ according to their very long-chain *n*-3 fatty acid content and the relative contributions of EPA and DHA (Table 2). Fig. 2 illustrates the estimated influence of daily consumption of a 1 g standard fish oil capsule, a 1 g 'concentrated' supplement, one teaspoon of cod liver oil, one meal of salmon and one or four capsules of a pharmaceutical grade preparation on daily intake of EPA + DHA. This shows that a person who does not consume fatty fish or *n*-3 fatty acid supplements can markedly increase their EPA + DHA intake through dietary change or through use of supplements.

**Table 1.** Typical content of EPA, docosapentaenoic acid (DPA) and DHA (g/100 g food) in a selection of seafood and meat

Food	EPA	DPA	DHA	Typical adult portion size (g)	EPA + DPA + DHA (g/portion)
Mackerel	0.71	0.12	1.10	160	3.09
Canned pilchards	1.17	0.23	1.20	110	2.86
Trout	0.23	0.09	0.83	230	2.65
Salmon	0.50	0.40	1.30	100	2.20
Canned sardines	0.89	0.10	0.68	100	1.67
Herring	0.51	0.11	0.69	120	1.56
Crab	0.47	0.08	0.45	85	0.85
Plaice	0.16	0.04	0.10	130	0.39
Cod	0.08	0.01	0.16	120	0.30
Mussels	0.41	0.02	0.16	40	0.24
Haddock	0.05	0.01	0.10	120	0.19
Venison	0.04	0.09	< 0.01	120	0.16
Canned tuna	0.02	0.02	0.14	45	0.08
Lamb	0.03	0.04	0.02	90	0.08
Prawns	0.06	< 0.01	0.04	60	0.06
Chicken	0.01	0.02	0.03	100	0.06
Beef	0.02	0.02	0	90	0.04
Pork	0.01	0.02	0.01	90	0.04

Data are taken from ref. 15. Note that both very long-chain *n*-3 fatty acid content and portion size may vary. Modified from ref. 3 with permission from John Wiley and Sons.

**Table 2.** Typical EPA and DHA contents of *n*-3 supplements

	EPA (mg/g oil)	DHA (mg/g oil)	EPA + DHA (mg/g oil)
Cod liver oil	110	90	200
Krill oil	140	65	205
Standard fish oil	180	120	300
Typical 45% fish oil concentrate	270	180	450
Tuna oil	110	350	460
Algal oil used in infant formula	0	>400	>400
Typical 60% fish oil concentrate	360	240	600
Omacor <sup>®</sup> * ( <i>n</i> -3 ethyl ester concentrate)	460	380	840
Flaxseed oil	0	0	0

Reproduced from ref. 16 with permission from John Wiley and Sons.


\* Also known as Lovaza<sup>®</sup>.

### Increased intake of EPA and DHA leads to increased content of EPA and DHA in blood, cells and tissues

As for all long-chain and very long-chain fatty acids, EPA and DHA are transported in the bloodstream esterified into TAG, phospholipids and cholesteryl esters as components of lipoproteins. They also occur in the bloodstream in the non-esterified form non-covalently bound to albumin. EPA and DHA are stored in adipose tissue esterified into TAG and they are found in all cell membranes esterified into phospholipids and related complex lipids. Cell membrane phospholipids and their fatty acid composition are important in determining the physical characteristics of cell membranes<sup>(21)</sup>, the manner in which membranes change in response to external stimuli<sup>(22)</sup> and the functional activities of membrane-bound

proteins<sup>(23)</sup>. EPA and DHA circulating in the bloodstream, stored in adipose tissue, and present in cell membranes may be regarded as transport, storage and functional pools, respectively. The contribution of EPA or DHA to the total fatty acids present within any of the transport, storage or functional pools differs according to the pool (Table 3)<sup>(24–36)</sup>. DHA is most often present in a greater concentration than EPA (Table 3). This is especially true in specific regions of the eye and brain where DHA makes a significant contribution to the fatty acid complement and EPA is virtually absent<sup>(27,28,37)</sup>. Within cell membranes, EPA and DHA are distributed differently among the different phospholipid components and in the brain and eye specific phospholipids are especially rich in DHA<sup>(37,38)</sup>.

Increased intakes of EPA and DHA from fish or from supplements are reflected in increased concentrations (and proportions) of both fatty acids in blood lipids, blood cells and many tissues. This has been reported many times for total plasma and serum lipids and for the complex lipid components of plasma and serum (i.e. TAG, phospholipids and cholesteryl esters)<sup>(24,39–47)</sup>. It is also well described for erythrocytes<sup>(24,42,43,47)</sup>, platelets<sup>(24,39,48)</sup> and leucocytes<sup>(24,26,44–46,49)</sup>. When their intake is increased, the content of EPA and DHA increases in several human tissues, including skeletal muscle<sup>(31)</sup>, heart<sup>(29)</sup>, gut mucosa<sup>(35,50)</sup> and adipose tissue<sup>(24,43)</sup>. There is a dose- and time-dependent pattern of incorporation of both EPA and DHA<sup>(24,26,39,43–46)</sup>. Although EPA is incorporated more quickly than DHA<sup>(24,43)</sup>, the precise pattern of EPA and DHA incorporation that occurs depends upon the specific nature of the lipid pool<sup>(24,43)</sup>. Pools that are turning over rapidly show faster incorporation of EPA and DHA than slower turning over pools. For example, plasma lipids incorporate EPA and DHA more quickly than blood cells<sup>(24,43)</sup>,



**Fig. 2.** Typical intake of EPA+DHA from the background diet in an adult not regularly consuming fatty fish and what would be achieved by also consuming a 1 g standard fish oil (FO) capsule, a 1 g ‘concentrated’ supplement, one teaspoon of cod liver oil, one meal of salmon, or one or four capsules of the pharmaceutical grade preparation Omacor®. Reproduced from ref. 3 with permission from John Wiley and Sons.

and amongst blood cells, leucocytes have been usually shown to incorporate EPA and DHA more quickly than erythrocytes. However, dose- and time-dependence of EPA and DHA incorporation into tissues is not well investigated in human subjects, apart from for adipose tissue<sup>(24,43)</sup>. Modification of human brain fatty acid composition is more difficult than for other tissues, especially beyond childhood.

The higher concentration of EPA and DHA achieved in various lipid pools through increased intake of EPA and DHA is maintained so long as the higher intake of EPA and DHA is maintained. If, after a period of increased intake of EPA and DHA, intake returns to the earlier lower level, then EPA and DHA concentrations decline, eventually returning to earlier levels. This is well described for blood lipids<sup>(39,43,44)</sup>, platelets<sup>(39)</sup>, leucocytes<sup>(44)</sup> and erythrocytes<sup>(43,47)</sup>. Just as the incorporation of EPA into different pools is faster than the incorporation of DHA, the loss of EPA is faster than the loss of DHA<sup>(39,43,44,47)</sup>. The better retention of DHA than EPA may be because DHA is structurally and/or functionally preferred over EPA and that metabolic mechanisms have evolved to preserve it.

### Molecular and cellular effects of increased EPA and DHA content

Many, though not all, of the functional effects of EPA and DHA are considered to require their incorporation into cell membrane phospholipids<sup>(51–53)</sup> (Fig. 3). EPA and DHA are highly unsaturated and as a consequence they have been shown in some studies to decrease membrane order (i.e. increase membrane fluidity)<sup>(21,54)</sup>, although cells have mechanisms such as modifying

membrane cholesterol content, to limit this effect. Through modulation of the physical properties of membranes, EPA and DHA provide a specific environment for membrane proteins like receptors, transporters, ion channels and signalling enzymes to function<sup>(22,23,55)</sup>. As a result, EPA and DHA can modulate cell responses that are dependent upon membrane protein function. This has been shown to be especially important in the eye where the presence of DHA enables optimal activity of the photoreceptor protein rhodopsin<sup>(56)</sup>. Cell membranes contain microdomains called rafts<sup>(57)</sup>. These have specific lipid and fatty acid compositions and act as platforms for receptor action and for the initiation of intracellular signalling pathways<sup>(57–59)</sup>. EPA and DHA can modify raft formation in a variety of cell types including neurons, immune cells and cancer cells<sup>(59–61)</sup>, so affecting intracellular signalling pathways<sup>(59–62)</sup>. As a result of their effects on membrane-generated intracellular signals, EPA and DHA can modulate transcription factor activation and, subsequently, gene expression patterns in a variety of cell types<sup>(51,55,63)</sup>. NF-κB<sup>(64)</sup>, the peroxisome proliferator activated receptors<sup>(65,66)</sup>, and the sterol regulatory element binding proteins<sup>(67–71)</sup> are amongst the transcription factors shown to be affected by EPA and DHA. The effects of EPA and DHA on transcription factor activation and modulation of gene expression are central to their role in controlling fatty acid and TAG metabolism, inflammation and adipocyte differentiation<sup>(51–53,55,63)</sup>.

Increased abundance of EPA and DHA in cell membrane phospholipids is associated with decreased abundance of the *n*-6 PUFA ARA<sup>(26,39,44,45,72)</sup>. This alters the availability of substrates for synthesis of bioactive lipid mediators (Fig. 4). ARA is quantitatively the major substrate for the biosynthesis of various prostaglandins, thromboxanes and leukotrienes, together termed eicosanoids, which have well-established roles in regulation of inflammation, immunity, platelet aggregation, smooth muscle contraction and renal function. Eicosanoids are oxidised derivatives of 20-carbon PUFA and are produced via the cyclooxygenase (prostaglandins, thromboxanes), lipoxygenase (leukotrienes and other products) and cytochrome P450 pathways. Although they have a number of obvious important physiological roles, excess or inappropriate production of eicosanoids from ARA is associated with many disease processes<sup>(73,74)</sup>. Increasing the EPA and DHA content of cell membranes results in decreased production of eicosanoids from ARA<sup>(39,45)</sup>, resulting in an impact of EPA and DHA on inflammation, immune function, blood clotting, vasoconstriction, and bone turnover amongst other processes. In addition to decreasing production of eicosanoids from ARA, EPA and DHA are themselves substrates for the synthesis of lipid mediators (Fig. 4). Some of these are simply analogues of those produced from ARA. For example, PG E<sub>3</sub> produced from EPA is an analogue of PG E<sub>2</sub> produced from ARA. Frequently, though not always, the EPA-derived mediator has weaker biological activity than the mediator derived from ARA<sup>(75)</sup>. For example, thromboxane A<sub>3</sub> produced from EPA is a much weaker platelet

**Table 3.** Typical EPA and DHA concentrations reported in different lipid pools in human subjects

Population	Lipid pool	EPA	DHA	Reference
Generally healthy men and women aged 20–80 years; UK	Plasma TAG*	0.3	0.8	(24)
Generally healthy men and women aged 20–80 years; UK	Plasma phospholipids*	1.2	3.6	(24)
Healthy pregnant women aged 18–40 years; week 38 of pregnancy; UK	Plasma phospholipids*	0.4	3.8	(25)
Newborn infants (umbilical cord); healthy pregnancies; UK	Plasma phospholipids	0.3	6.4	(25)
Generally healthy men and women aged 20–80 years; UK	Plasma cholesteryl esters*	1.0	0.6	(24)
Generally healthy men and women aged 20–80 years; UK	Plasma NEFA*	0.4	1.6	(24)
Generally healthy men and women aged 20–80 years; UK	Erythrocytes	2.3	5.2	(24)
Generally healthy men and women aged 20–80 years; UK	Platelets	1.1	2.0	(24)
Generally healthy men aged 18–40 years; UK	Blood neutrophils	0.6	1.6	(26)
Generally healthy men and women aged 20–80 years; UK	Blood mononuclear cells (mainly lymphocytes)	0.8	1.9	(24)
Men mean age 68 years with no evidence of dementia	Brain grey matter	Not reported	18	(27)
Men mean age 68 years with no evidence of dementia	Brain white matter	Not reported	4	(27)
Breast-fed term infants who had died at mean age 4 months; Australia	Cerebral cortex	<0.1	8	(28)
Breast-fed term infants who had died at mean age 4 months; Australia	Retina	0.1	12	(28)
Men mean age 55 years who had received a heart transplant; USA	Cardiac muscle	0.2	1.5	(29)
Mainly men mean age 60 years undergoing cardiac surgery; Australia	Cardiac muscle phospholipids	0.5	4.8	(30)
Healthy men mean age 21 years; UK	Skeletal muscle	0.6	1.5	(31)
Healthy men and women aged 25–45 years; USA	Skeletal muscle phospholipids	0.7	1.9	(32)
Men and women aged 38–41 years undergoing surgery; Chile	Liver	0.4	6.8	(33)
Men and women aged 23–63 years undergoing surgery; Chile	Liver phospholipids	4.8	15.1	(34)
Patients with inflammatory bowel disease; UK	Colonic mucosa	0.3	1.7	(35)
Generally healthy men and women aged 20–80 years; UK	Subcutaneous adipose tissue	0.2	0.2	(24)
Generally healthy men mean age 34 years; Iran	Spermatozoa	0.6	9.6	(36)

Data are taken from the selected references and are expressed as % of total fatty acids. Reproduced from ref. 16 with permission from John Wiley and Sons.  
\* Blood collected after an overnight fast.


aggregator than thromboxane A<sub>2</sub> produced from ARA<sup>(76)</sup>. EPA and DHA are also substrates for more complex biosynthetic pathways that result in generation of mediators known as resolvins (E-series formed from EPA and D-series formed from DHA), protectins/neuroprotectins (formed from DHA) and maresins (formed from DHA)<sup>(77–79)</sup> (Fig. 4). It has recently been discovered that DPA gives rise to a similar family of mediators<sup>(5,80)</sup>. The major role of resolvins, protectins and maresins appears to be in the resolution of inflammation and modulation of immune function<sup>(77–79)</sup>. It seems likely that many of the anti-inflammatory and immune modulating actions of EPA and DHA that are described in the literature<sup>(52,53,72,81)</sup> are mediated through resolvins, protectins and maresins.

The above-mentioned mechanisms of action of EPA and DHA rely upon incorporation of those fatty acids into cell membrane phospholipids (Fig. 3). It is now recognised that EPA and DHA (in their non-esterified form) can also act directly via membrane G-protein coupled receptors that exhibit some specificity for very long-chain *n*-3 fatty acids over other fatty acids as ligands<sup>(82)</sup>. In particular, free fatty acid receptor 4 (also known as GPR120), which is highly expressed on inflammatory macrophages and on adipocytes, was shown in cell culture experiments to play a central role in mediating the anti-inflammatory effects of DHA on macrophages and the insulin-sensitising effects of DHA on adipocytes<sup>(82)</sup>.


### Roles of EPA and DHA in supporting optimal cell and tissue function and promoting health

#### CVD

Native populations in Greenland, Northern Canada and Alaska consuming their traditional diet were found to have much lower rates of death from CVD than predicted, despite their high dietary fat intake<sup>(83–86)</sup>. The protective component of the diet was suggested to be the very long-chain *n*-3 fatty acids consumed in very high amounts as a result of the regular intake of seal and whale meat, whale blubber and fatty fish<sup>(87)</sup>. Low cardiovascular mortality is also seen in Japanese consuming a traditional diet<sup>(88)</sup> and this diet is rich in seafood including fatty fish and sometimes marine mammals, which contain significant amounts of EPA and DHA. Much evidence has now accumulated from prospective and case-control studies indicating that higher intake of EPA and DHA is associated with reduced risk of CVD outcomes in Western populations, although not all studies agree. These studies have been summarised and discussed in detail elsewhere<sup>(89–93)</sup> and they have been subject to systematic review and meta-analysis. For example, Chowdhury *et al.*<sup>(94)</sup> brought together prospective studies examining the association of dietary or circulating fatty acids, including very long-chain *n*-3 fatty acids, with risk of coronary outcomes. Data from sixteen studies involving over 422 000 individuals showed a relative risk of 0.87 for



**Fig. 3.** General overview of the mechanisms by which very long-chain *n*-3 fatty acids can influence the function of cells. Modified from Calder<sup>(72)</sup>, Copyright (2011), with permission from Elsevier.



**Fig. 4.** Overview of the bioactive lipid mediators produced from arachidonic acid, EPA and DHA.

those in the top third of dietary intake of very long-chain *n*-3 fatty acids compared with those in the lower third of intake. Data from thirteen studies involving over 20 000 individuals showed relative risks of 0.78, 0.79 and 0.75 for those in the top third of circulating EPA, DHA and EPA + DHA, respectively, compared with those in the lower third<sup>(94)</sup>. A smaller number of studies in fewer individuals gave a relative risk of 0.64 for circulating DPA<sup>(94)</sup>. A more recent analysis pooled data from nineteen studies that investigated the association between EPA or DHA concentration in a body compartment like plasma, serum, erythrocytes or adipose tissue and risk of future CHD in adults who were healthy at study entry<sup>(95)</sup>. EPA and DHA were each associated with a lower risk of fatal CHD, with relative risks of 0.91 and 0.90, respectively<sup>(95)</sup>. These analyses<sup>(94,95)</sup> support a clear role for EPA and DHA in primary prevention of CHD, and perhaps, more widely, of CVD, as discussed elsewhere<sup>(96)</sup>.

Beneficial modification of a broad range of risk factors probably explains the protective effect of very long-chain *n*-3 fatty acids towards CHD. These risk factors include plasma/serum TAG concentrations, blood pressure, thrombosis, cardiac function, vascular function and inflammation, which are all improved by very long-chain *n*-3 fatty acids<sup>(89,93,97–101)</sup>. A recent meta-analysis of randomised controlled trials (RCT) evaluated the effects of EPA + DHA on a range of risk factors for CVD<sup>(102)</sup>; the findings are summarised in Table 4. Significant effects of EPA + DHA were identified for plasma/serum TAG and HDL cholesterol concentrations, systolic and diastolic blood pressure, heart rate and C-reactive protein concentration, a marker of inflammation (Table 4). There was also a significant elevation of LDL concentration (Table 4), but this apparently deleterious effect may be offset by an increased size of LDL particles<sup>(103)</sup>, rendering them less atherogenic. The improvement in the risk factor profile with very long-chain *n*-3 fatty acids would account for the lowered risk of coronary disease reported in many previous epidemiological studies and identified in the recent meta-analysis<sup>(94)</sup> and pooled analysis<sup>(95)</sup> of cohort studies.

A role in prevention of CVD is an obvious important health benefit of EPA + DHA. There has also been great interest in the ability of very long-chain *n*-3 fatty acids to treat people with existing CVD. The outcome in studies in this area has most often been the occurrence of a major cardiovascular event (e.g. myocardial infarction (MI)), fatal MI, or death. Several large studies published between 1989 and 2008 reported lower rates of death in patients receiving very long-chain *n*-3 fatty acids<sup>(104–108)</sup>. Doses of very long-chain *n*-3 fatty acids used in these studies were 500 mg to 1.6 g/d and durations of intervention were 1–5 years. As a result of these positive findings, meta-analyses published in the period 2002–2009 supported that very long-chain *n*-3 fatty acids lower mortality in patients with existing CVD<sup>(109–111)</sup>. For example, a meta-analysis including eleven studies involving almost 16 000 patients reported that, compared with control, very long-chain *n*-3 fatty acids lower the risk of fatal MI, sudden death and all-cause mortality (relative risks 0.7, 0.7 and 0.8, respectively)<sup>(109)</sup>. A second meta-analysis including fourteen studies involving over 20 000 patients reported that, compared with control, very long-chain *n*-3 fatty acids lower the risk of cardiac mortality and all-cause mortality (relative risks 0.68 and 0.77, respectively)<sup>(110)</sup>. It is likely that the mechanisms that reduce the likelihood of cardiovascular events and mortality in patients with established disease are different from the mechanisms that act to slow the development of atherosclerosis. Three key mechanisms have been suggested to contribute to this therapeutic effect of very long-chain *n*-3 fatty acids. The first is altered cardiac electrophysiology seen as lower heart rate<sup>(112)</sup>, increased heart rate variability<sup>(113)</sup> and fewer arrhythmias<sup>(114)</sup>. These effects make the heart more able to respond robustly to stress. The second is an anti-thrombotic action resulting from the altered pattern of production of eicosanoid mediators from ARA and from EPA that control platelet aggregation<sup>(39)</sup>. This effect would lower the likelihood of clot formation or would result in weaker clots less able to stop blood

**Table 4.** Summary of the effects of very long-chain *n*-3 fatty acids on risk factors for CVD identified through the meta-analysis of AbuMweis *et al.*<sup>(102)</sup>

Risk factor	Number of studies included	Effect size (95% CI)	<i>P</i>
Plasma/serum TAG concentration (mM)	110	-0.368 (-0.427, -0.309)	0.0001
Plasma/serum total cholesterol concentration (mM)	108	-0.051 (-0.166, 0.064)	0.387
Plasma/serum LDL cholesterol concentration (mM)	100	0.150 (0.058, 0.243)	0.001
Plasma/serum HDL cholesterol concentration (mM)	110	0.039 (0.024, 0.054)	0.0001
Systolic blood pressure (mm Hg)	50	-2.195 (-3.172, -1.217)	0.0001
Diastolic blood pressure (mm Hg)	50	-1.08 (-1.716, -0.444)	0.0001
Heart rate (beats per minute)	26	-1.370 (-2.415, -0.325)	0.01
C-reactive protein (mg/l)	20	-0.343 (-0.454, -0.232)	0.0001
Flow-mediated dilatation (%)	6	1.460 (-0.475, 3.395)	0.139

**Table 5.** Some of the current recommendations for intake of very long-chain *n*-3 fatty acids

Recommending organisation	Population subgroup	Recommendation	Reference
(UK) Scientific Advisory Committee on Nutrition/Committee on Toxicity	Adults in the general population	At least two portions of fish per week, at least one of which is fatty fish; equated to 450 mg EPA + DHA daily	(17)
International Society for the Study of Fatty Acids and Lipids	Adults in the general population	Minimum of 500 mg EPA + DHA daily; Target of 650 mg EPA + DHA daily	(262,263)
French Agency for Food, Environmental and Occupational Health Safety	Adults in the general population	Target of 400–500 mg EPA + DHA daily with at least 100–120 mg DHA daily	(264)
(Australian) National Health and Medical Research Council	Adults in the general population	Target of 430–610 mg EPA + DHA daily	(265)
Food and Agricultural Organisation of the UN	Adult males and non-pregnant or non-lactating adult females	Minimum of 250 mg EPA + DHA daily	(266)
Food and Agricultural Organisation of the UN	Pregnant or lactating females	Minimum of 300 mg EPA + DHA daily of which at least 200 mg should be DHA	(266)
Food and Agricultural Organisation of the UN	Children aged 2–4 years	100–150 mg EPA + DHA daily	(266)
Food and Agricultural Organisation of the UN	Children aged 4–6 years	150–200 mg EPA + DHA daily	(266)
Food and Agricultural Organisation of the UN	Children aged 6–10 years	200–250 mg EPA + DHA daily	(266)
European Food Safety Authority	Adult males and non-pregnant adult females	Adequate intake is 250 mg EPA + DHA daily	(267)
European Food Safety Authority	Pregnant females	An additional 100–200 mg DHA daily	(267)
European Food Safety Authority	Infants and children aged 6 months to 2 years	100 mg DHA daily	(267)
European Food Safety Authority	Children aged 2–18 years	'consistent with adults'	(267)
American Heart Association	Patients who have had a recent myocardial infarction	1000 mg EPA + DHA daily in concentrated form	(89,129)
American Heart Association	For patients with elevated blood TAG concentrations	2000–4000 mg EPA + DHA daily	(89)

flow to affected organs. The third mechanism is the well-documented anti-inflammatory effect of very long-chain *n*-3 fatty acids, which would serve to stabilise atherosclerotic plaques preventing their rupture<sup>(115,116)</sup>. This effect would reduce the likelihood of a cardiovascular event (MI, stroke) from happening<sup>(117)</sup>. Thus, there is a biological plausibility to EPA + DHA having a benefit in secondary prevention of cardiovascular events and mortality.

Despite the positive findings with very long-chain *n*-3 fatty acids, supported by meta-analyses and biologically plausible candidate mechanisms, more recent studies in patients with existing CVD have failed to replicate the earlier findings<sup>(118–122)</sup>. This has influenced some of the

most recent meta-analyses, which have concluded that there is little protective effect of very long-chain *n*-3 fatty acids on cardiovascular mortality<sup>(123–125)</sup>. Nevertheless, the meta-analysis by Rizos *et al.*<sup>(125)</sup> which included the recent studies, but excluded the landmark GISSI Prevenzione trial<sup>(105)</sup>, did identify a reduction in cardiac death with very long-chain *n*-3 fatty acids (relative risk 0.91) and trends towards reductions in sudden death and MI (relative risks 0.91 and 0.89, respectively). It is important to recognise that the most recent studies of very long-chain *n*-3 fatty acids and cardiovascular mortality have been criticised for various reasons related to small sample size, the low dose of EPA + DHA used, the too short duration of follow up,



and, in some studies, the low rate of events<sup>(126)</sup>. Despite this, meta-analyses that include the GISSI-Prevenzione study and some of the more recent neutral studies, still report benefits from very long-chain n-3 fatty acids<sup>(127,128)</sup>. For example, Casula *et al.*<sup>(127)</sup> identified reductions in cardiac death, sudden death and MI (relative risks 0.68, 0.67 and 0.75, respectively) with very long-chain n-3 fatty acids and a trend towards lower all-cause mortality (relative risk 0.89). Likewise, Wen *et al.*<sup>(128)</sup> identified reductions in cardiac death, sudden death, MI and all-cause mortality (relative risks 0.88, 0.86, 0.86 and 0.92, respectively) with very long-chain n-3 fatty acids.

Thus, there is a significant literature gathered over more than 45 years from association studies, from RCT investigating the impact on risk factors, and from RCT investigating the effect on hard clinical outcomes like mortality that very long-chain n-3 fatty acids lower the risk of developing CVD, especially CHD and can be used to treat people with CVD. Although the most recent RCT in patients with CVD have produced findings that do not agree with the previously accumulated literature, it is too early to discard the earlier evidence. Instead reasons to explain the different findings need to be identified, in order to better understand the actions of EPA and DHA. The conclusion that very long-chain n-3 fatty acids have a role in reducing risk of CVD, especially CHD, remains well supported, for example by the American Heart Association<sup>(89,129)</sup>.

### Cancer

EPA and DHA have a number of biological activities that may influence tumour cell viability and proliferation. For example, DHA can promote tumour cell apoptosis<sup>(130,131)</sup>, possibly through inducing oxidative stress. The replacement of ARA in cell membranes by EPA and DHA is also an important anti-cancer mechanism of action of n-3 PUFA, since ARA-derived eicosanoids like PG E<sub>2</sub> and leukotriene B<sub>4</sub> promote tumour cell proliferation, survival, migration and invasion<sup>(131–133)</sup>. Through these effects, EPA and DHA can directly influence cancer cells and the tumour environment, and they can also influence the host response to tumour bearing. Recent reviews provide a detailed description of the mechanisms by which very long-chain n-3 fatty acids affect tumour cell proliferation, survival, invasion and metastasis<sup>(130,131)</sup>; the ability of very long-chain n-3 fatty acids to enhance the effectiveness of anti-cancer treatments<sup>(131,133)</sup>; and the current evidence of the efficacy of very long-chain n-3 fatty acids in human subjects in the context of cancer and its treatment<sup>(131,133)</sup>.

Some prospective and case-control studies show that very long-chain n-3 fatty acids are associated with lower risk of colorectal and breast cancers, but there is inconsistency in the findings from such studies<sup>(134)</sup>. Recent systematic reviews conclude that very long-chain n-3 fatty acids are protective against colorectal<sup>(135)</sup> and breast<sup>(136)</sup> cancers, while a fairly recent prospective cohort study among post-menopausal women found

that higher dietary intake of either EPA or DHA was associated with lower risk of developing breast cancer<sup>(137)</sup>. Whether very long-chain n-3 fatty acids increase or decrease risk of prostate cancer is currently under debate<sup>(138,139)</sup>.

In addition to effects that lower the risk of developing some forms of cancer, there seems to be a role for very long-chain n-3 fatty acids in patients who already have cancer. For example, quality of life and physical functioning can be improved in cancer patients with oral provision of very long-chain n-3 fatty acids. A systematic review<sup>(140)</sup> concluded that lung cancer patients receiving supplements containing EPA and DHA had improved appetite, energy intake, body weight and quality of life. Breast cancer patients with a higher concentration of very long-chain n-3 fatty acids in their bloodstream had lower inflammation and less physical fatigue than seen in patients with a lower concentration of very long-chain n-3 fatty acids<sup>(141)</sup>. Lung cancer patients given 1.8 g EPA + DHA daily had improved appetite and less fatigue than controls<sup>(142)</sup>. Van der Meij *et al.*<sup>(143)</sup> reported improved quality of life, physical function, cognitive function and health status in patients with non-small cell lung cancer receiving 2.9 g EPA + DHA per day. The patients receiving very long-chain n-3 fatty acids also tended to have greater physical activity compared with the control group<sup>(143)</sup>.

EPA and DHA sensitise cultured tumour cells to chemotherapeutic agents, increasing the efficacy of those agents<sup>(144)</sup>. The mechanism by which this occurs is not clear, but it might involve increased EPA and DHA content of tumour cell membranes resulting in increased lipid peroxidation in those membranes in the presence of the cancer therapeutic. If this occurred *in vivo* it would result in improved efficacy of the therapy and perhaps reduced side effects. Murphy *et al.*<sup>(145)</sup> conducted a trial in patients with non-small cell lung cancer and showed that 2.5 g EPA + DHA daily caused a 2-fold increase in response rate to the chemotherapy being used and prolonged the period over which patients could receive the chemotherapy. They also reported a trend towards improved survival with very long-chain n-3 fatty acids. Bougnoux *et al.*<sup>(146)</sup> reported improved chemotherapy outcomes in breast cancer patients receiving 1.8 g DHA daily.

Cancer cachexia (loss of lean and fat tissue) is a complication that occurs in patients with advanced solid tumors and greatly increases risk of mortality. Weed *et al.*<sup>(147)</sup> reported that patients with squamous cell cancer of the head and neck taking 3.08 g EPA + DHA daily had increased lean body mass. Murphy *et al.*<sup>(148)</sup> showed that 2.2 g EPA + DHA daily was able to maintain body weight and muscle mass during chemotherapy in patients with non-small cell lung cancer. In other studies in patients with cancer, very long-chain n-3 fatty acids increased body weight<sup>(149,150)</sup>.

Thus, there is increasing evidence from studies in human subjects that very long-chain n-3 fatty acids have a role in reducing risk of developing some cancers, particularly colorectal and breast. Furthermore, a number of intervention trials demonstrate that very long-



chain *n*-3 fatty acids have a range of benefits in patients with various types of cancer. Most intervention studies have used approximately 2 g/d EPA + DHA. From their review of the literature Vaughan *et al.*<sup>(133)</sup> concluded 'There is now sufficient literature to suggest that the use of supplements containing EPA and DHA may have potential use as an effective adjuvant to chemotherapy treatment and may help ameliorate some of the secondary complications associated with cancer. . . . our investigations indicate that supplementation with fish oil or EPA/DHA (>1 g EPA and >0.8 g DHA daily) is associated with positive clinical outcomes.'

### *Inflammation*

Inflammation is an essential component of normal host defence mechanisms, initiating the immune response and later playing a role in tissue repair. The inflammatory response is normally self-limiting (i.e. resolving) in order to protect the host from damage. However, the loss of the normal mechanisms inducing tolerance (e.g. to self, to endogenous commensal micro-organisms, or to environmental components such as foods) or loss of resolving factors can allow inflammation to become chronic and in this state the damage done to host tissues may become pathological<sup>(151,152)</sup>. As such, inflammation is the central adverse response seen in a range of conditions including rheumatoid arthritis (RA), inflammatory bowel disease, multiple sclerosis, asthma, psoriasis, and atopic dermatitis. Furthermore, chronic low-grade inflammation is now recognised to be a contributor to CVD<sup>(153,154)</sup> and to play a role in cardiometabolic diseases like obesity, type-2 diabetes and non-alcoholic fatty liver disease and in cognitive decline<sup>(155)</sup>. Cancer also has a permissive inflammatory component<sup>(156)</sup>.

Eicosanoids and related lipid mediators provide a direct link between fatty acids and inflammatory processes. As described earlier, the *n*-6 PUFA ARA is the precursor for the production of prostaglandins and leukotrienes that are directly involved in inflammatory processes<sup>(73,74)</sup>. In contrast to the effects of ARA, EPA and DHA give rise to mediators which are less pro-inflammatory, anti-inflammatory or inflammation resolving<sup>(52,53,72,77–79,81)</sup>. In addition to their effects on lipid mediators (prostaglandins, leukotrienes, resolvins, protectins, maresins), EPA and DHA modulate many other aspects of inflammatory processes including leucocyte migration and production of inflammatory cytokines<sup>(52,53,72,81)</sup>. These effects on inflammation relate to the modulation of cell signalling, transcription factor activation and gene expression by EPA and DHA. There is good evidence that EPA and DHA given in combination at sufficiently high doses are anti-inflammatory and have a therapeutic role in inflammatory diseases. This has been most widely studied in RA<sup>(157)</sup>, inflammatory bowel disease<sup>(158)</sup> and asthma<sup>(159)</sup>. Evidence of efficacy is strongest in RA, although high doses (several g/d EPA + DHA) are typically used<sup>(157)</sup>. Recent systematic reviews and meta-analyses have highlighted the benefits of EPA + DHA on arthritic pain<sup>(160,161)</sup>.

Allergic disease begins in infancy and the immune imbalances that predispose to allergy may be influenced by the relative exposure to *n*-6 and *n*-3 PUFA<sup>(162)</sup>. Therefore, there has been significant interest in whether increased intake of very long-chain *n*-3 fatty acids by pregnant and breast-feeding women will reduce the risk of allergic disease in their babies. There is some evidence that increased intake of EPA and DHA during human pregnancy has an effect on the immune system of the baby<sup>(163–165)</sup> and that this is linked to reduced allergic symptoms later in childhood<sup>(163,166,167)</sup>. Best *et al.*<sup>(168)</sup> reported a meta-analysis of offspring clinical outcomes from trials of increased maternal intake of very long-chain *n*-3 fatty acids in pregnancy. They identified lower risk of atopic eczema, and less likelihood of having a positive skin prick test to any allergen tested, to hens' egg, or to any food extract, all in the first 12 months of life. A recent study reported that fish oil consumption by pregnant women decreased risk of persistent wheeze and asthma in the offspring at ages 3–5 years<sup>(169)</sup>. Supplementing the diets of very young infants has also now been shown to have immune effects consistent with reduced likelihood of allergy<sup>(170)</sup>. This area of research has been reviewed recently<sup>(171–173)</sup>.

Thus, the anti-inflammatory actions of EPA and DHA are extensively demonstrated and the underlying mechanisms are increasingly understood. High doses of very long-chain *n*-3 fatty acids can be used to treat frank inflammatory conditions like RA, while lower doses likely have a role in protecting against development of childhood allergic disease and low-grade inflammatory conditions in adulthood.

### *Neurocognitive health*

More than 50% of the dry weight of the brain is lipid, particularly structural and functional lipid (i.e. phospholipids). The human brain and retina contain an especially high proportion of DHA relative to other tissues but little EPA (Table 3). Grey matter phosphatidylethanolamine contains 24% of its fatty acids as DHA, whereas grey matter phosphatidylserine contains 37% of its fatty acids as DHA<sup>(174)</sup>. DHA contributes 50–70% of the fatty acids present in the rod outer segments of the retina<sup>(38)</sup>. These rod outer segments contain the eye's photoreceptors and DHA has been clearly shown to be essential for optimal visual functioning<sup>(56)</sup>. DHA is important for neurotransmission, neuronal membrane stability, neuroplasticity and signal transduction<sup>(174–176)</sup>. An adequate supply of very long-chain *n*-3 fatty acids, especially DHA, seems essential for optimal visual, neural and behavioural development of the infant/child. The need for DHA so early in life was demonstrated in studies conducted in the 1980s and 1990s with pre-term infants, where formulas that included DHA (and often also ARA) were shown to improve visual development<sup>(177–182)</sup>. However, a recent meta-analysis of seventeen trials of inclusion of DHA (and ARA) in infant feeds involving 2260 preterm infants found little evidence to support improved visual acuity or neurodevelopment, although three out of seven studies of neurodevelopment



did report some benefit of the PUFA<sup>(183)</sup>. Studies of DHA in preterm infants are discussed in detail elsewhere<sup>(184)</sup>. The literature on the effect of DHA on visual and cognitive outcomes in term infants is mixed with some studies reporting benefits<sup>(185,186)</sup> and others not<sup>(187–190)</sup>. One reason for this might be that an early beneficial effect of DHA is lost with time so that early assessments show benefit and later assessments do not; at least one study has shown this<sup>(185,191)</sup>. A recent meta-analysis of fifteen trials of inclusion of DHA (and ARA) in infant feeds involving 1889 term infants found little evidence to support improved visual or neurodevelopment, although four out of nine studies of visual acuity and two out of eleven studies of cognitive development reported benefit<sup>(192)</sup>. Despite the inconsistencies in the literature, it still seems important that pregnant and breastfeeding women and infants consuming formula instead of breast milk have adequate intakes of very long-chain *n*-3 fatty acids, especially DHA. A systematic review and meta-analysis of eleven RCT of very long-chain *n*-3 fatty acids in pregnancy involving over 5000 women could not conclusively support or refute that very long-chain *n*-3 fatty acids in pregnancy improve infant visual or cognitive development<sup>(193)</sup>.

Very long-chain *n*-3 fatty acids are likely to have important roles in the brain beyond infancy and are probably important for brain function throughout the life course. A number of studies have reported lower levels of EPA and DHA in the bloodstream of children with attention deficit hyperactivity disorder (ADHD) or autistic spectrum disorders than in control children<sup>(194)</sup>. It is possible that these and other developmental disorders might be related to some sort of fatty acid deficiency state. If this is the case, then normalisation of fatty acid levels should lead to clinical benefit in these conditions. This has been examined in a number of trials in children and adolescents with attention, learning, or behavioural disorders, some showing some improvements<sup>(195–205)</sup> and others finding no effect<sup>(206–214)</sup>. These trials have been reviewed many times, with differing conclusions. The different findings may relate to the dose of *n*-3 fatty acids used, the duration of supplementation, the precise outcome(s) measured and differences in the children studied. Indeed, one review concluded that studies using higher doses of very long-chain *n*-3 fatty acids or of longer duration or in children/adolescents with low socioeconomic status were more likely to find effects<sup>(215)</sup>. A recent meta-analysis of five RCT involving 189 children with autism spectrum disorder identified benefit of very long-chain *n*-3 fatty acids on some outcomes, but concluded that the limited number of studies and small sample sizes restrict the ability to make firm conclusions<sup>(216)</sup>. Another recent meta-analysis used data from fifteen case-control studies involving 1193 individuals with autism to show lower blood EPA, DHA and ARA and higher ratio of *n*-6 to *n*-3 PUFA in autism<sup>(217)</sup>. Data from four RCT involving 107 individuals with autism showed improvements in some outcomes with very long-chain *n*-3 fatty acids, but the authors suggested the need for larger and longer studies in order to be clear about the effect<sup>(217)</sup>. A meta-analysis of ten RCT

of very long-chain *n*-3 fatty acids in children with ADHD showed no improvements in measures of emotional lability, oppositional behaviour, conduct problems or aggression<sup>(218)</sup>. However, subgroup analyses of higher quality studies and those meeting strict inclusion criteria found a significant reduction in emotional lability and oppositional behaviour<sup>(218)</sup>. The authors concluded that a number of treatment effects may have failed to reach statistical significance due to small sample sizes and within and between study heterogeneity in terms of design and study participants<sup>(218)</sup>. In seven RCT involving 534 adolescents with ADHD, very long-chain *n*-3 fatty acids improved ADHD clinical symptom scores, while in three RCT involving 214 adolescents, very long-chain *n*-3 fatty acids improved cognitive measures associated with attention<sup>(219)</sup>. A very recent systematic review was supportive of use of *n*-3 fatty acid supplements in children with ADHD<sup>(220)</sup>.

Over 35 years ago Rudin suggested that mental disorders might result from a deficiency in very long-chain *n*-3 fatty acids and might respond to provision of these fatty acids<sup>(221)</sup>. Data from nine countries demonstrated a significant correlation between high annual fish consumption and lower prevalence of major depression<sup>(222)</sup>, an observation that is compatible with a proposed protective effect of very long-chain *n*-3 fatty acids. A reduction in depressive symptoms was reported in a small study using a very high dose of EPA + DHA (9.6 g/d)<sup>(223)</sup>, while this effect was not seen in a study using a lower dose of DHA alone (2 g/d)<sup>(224)</sup>. Intervention with 6.2 g/d EPA + DHA in patients with bipolar manic depression resulted in significant improvements in nearly all outcomes, especially with respect to depressive symptoms, after 4 months<sup>(225)</sup>. Likewise, 2 g/d EPA improved symptoms in patients with unipolar depressive disorder after 4 weeks<sup>(226)</sup>. A meta-analysis of thirteen RCT involving 1233 participants with major depressive disorder showed an overall beneficial effect of very long-chain *n*-3 fatty acids on depressive symptoms<sup>(227)</sup>; interestingly higher EPA dose was one factor associated with better outcome for *n*-3 PUFA supplementation. This finding fits with an earlier analysis of fifteen RCT investigating the effects of EPA, which concluded that supplements containing  $\geq 60\%$  EPA in doses ranging from 0.2 to 2.2 g/d EPA were effective against primary depression<sup>(228)</sup>. There is also evidence from meta-analysis that depressive symptoms seen in bipolar disorder may be improved by the adjunctive use of very long-chain *n*-3 fatty acids<sup>(229)</sup>. Another meta-analysis that included twenty-five studies involving 1373 participants identified a 'small-to-modest benefit' for depressive symptomatology with very long-chain *n*-3 fatty acids<sup>(230)</sup> but the authors expressed doubts about the robustness of their finding.

Schizophrenic patients have lower levels of EPA and DHA in their erythrocytes than do controls<sup>(231–235)</sup>. The first trial of very long-chain *n*-3 fatty acids in schizophrenia identified clinical improvement with EPA (2 g/d), but not with DHA<sup>(236)</sup>, while subsequent trials also showed benefit with EPA<sup>(237,238)</sup>, but not all studies have seen this<sup>(239)</sup>. A recent study reported significant benefits of very long-chain *n*-3 fatty acids given for 26



weeks to patients with schizophrenia<sup>(240)</sup>. Although these findings are encouraging, a Cochrane review concluded that very long-chain *n*-3 fatty acids should be regarded only as an experimental treatment for schizophrenia<sup>(241)</sup>. A study reported significant benefit from 1 g/d EPA in borderline personality disorder<sup>(242)</sup>, while a small number of studies report anti-aggressive effects of DHA<sup>(243,244)</sup>.

Post-mortem studies showed that the brains of people with Alzheimer's disease contain less DHA than those without the disease<sup>(245–248)</sup> and some studies have linked low blood levels of very long-chain *n*-3 fatty acids to dementia<sup>(249)</sup>. Sinn *et al.* reported that 1.8 g EPA + DHA daily for 6 months reduced depressive symptoms and improved cognition in adults with mild cognitive impairment<sup>(250)</sup>. Improved memory performance in subjects with mild Alzheimer's disease was reported with 1.5 g EPA + DHA daily for 6 months<sup>(251)</sup>. However, a number of other studies using various doses and ratios of EPA and DHA reported no effect on cognitive performance in people with Alzheimer's disease<sup>(252–257)</sup>. Meta-analyses provide a mixed view of the findings for *n*-3 fatty acid treatment in the area of cognitive impairment, reflecting the mixed findings from individual trials. A Cochrane review of RCT studying the role of very long-chain *n*-3 fatty acids in preventing cognitive decline in healthy older people showed no benefits<sup>(258)</sup>, while two more recent meta-analyses differ in their findings. One meta-analysis of six RCT of duration 3–40 months and using 0.14–1.8 g EPA + DHA daily identified a slower rate of cognitive decline in those receiving very long-chain *n*-3 fatty acids<sup>(259)</sup>. In contrast, a meta-analysis of three RCT involving 632 participants with mild to moderate Alzheimer's disease and followed for 6, 12 or 18 months found no evidence of a benefit from very long-chain *n*-3 fatty acids on any outcome that was assessed<sup>(260)</sup>. A recent large trial found no effects of very long-chain *n*-3 fatty acids (0.225 g EPA plus 0.8 g DHA daily) over 3 years on cognitive decline<sup>(261)</sup>.

Thus, DHA is a key structural component of the brain and retina, where it plays particular, unique functional roles. A supply of DHA is very important early in life, especially during the fetal and early infant periods when the eye and central nervous system are developing. Since the supply must come from maternal sources (via the placenta and breast milk), maternal DHA status is likely to be important in determining eye and brain development early in life. Newly emerging areas of interest relate to the influence of very long-chain *n*-3 fatty acids on childhood developmental disorders, adult psychiatric and psychological disorders, and neurodegenerative diseases of ageing. These conditions appear to be associated with a lower status of very long-chain *n*-3 fatty acids. Additionally, there is some epidemiological evidence for a lowered risk of psychiatric, psychological disorders and neurodegenerative disorders with increased dietary intake of very long-chain *n*-3 fatty acids. Intervention studies indicate that there may be some benefit from very long-chain *n*-3 fatty acids in childhood developmental and adult psychiatric and psychological disorders, particularly in depression. Interestingly many

of these studies are indicative that EPA is more important than DHA, which contrasts with the relative roles of these two fatty acids in very early eye and brain development. Although there may be a role for very long-chain *n*-3 fatty acids in slowing cognitive decline<sup>(259)</sup>, this has not been well demonstrated<sup>(258,260)</sup>. There is a clear need for larger, longer and higher quality human trials in this area of research.

### Recommendations for intake of EPA and DHA acid

The demonstration of physiological actions of EPA and DHA that result in improved health outcomes and reduced risk of disease, along with the increased understanding of the molecular and cellular mechanisms of action involved, indicates a need to set recommendations for the intake of these important fatty acids. However, the exact requirement for very long-chain *n*-3 fatty acids in order to maintain health is not known. Furthermore, there has been a lack of clarity about the extent to which EPA and DHA can be synthesised in human subjects so long as there is sufficient intake of the precursor ALA<sup>(8)</sup>. Nevertheless, the recognition of the health benefits of EPA and DHA has resulted in several recommendations to increase the intake of fish and, more specifically, of EPA and DHA by various governmental, non-governmental and professional agencies<sup>(17,89,129,262–267)</sup>. These recommendations are summarised in Table 5.

### The future of research in *n*-3 PUFA

Very long-chain *n*-3 fatty acids have been a focus of research since the late 1980s, although important pioneering work in the field was performed before then. A PubMed search conducted in late August 2017 identified over 25 500 publications using the search term 'omega-3' and 28 500 publications using the search term 'fish oil'. The earliest publications identified using those terms were from 1922 and 1945, respectively, although the earliest of the almost 1000 publications identified with the search term 'cod liver oil' was from 1845. By 1990, there was a publication on the topic of *n*-3 fatty acids on average every day. By the mid-2010s this had risen to almost five publications every day. Thus, a tremendous effort has been, and is continuing to be, expended on research in the area of *n*-3 fatty acids. This research effort obviously falls into many categories, not all related to human health and well-being, although much of it does. Research aimed at better defining the roles that very long-chain *n*-3 fatty acids play in human growth, development, function, health, well-being and disease risk and better understanding the molecular and cellular mechanisms involved will continue for the foreseeable future. Despite the vast amount of knowledge that is currently available about *n*-3 PUFA, there remain significant gaps and inconsistencies in the literature that impair the ability to make robust recommendations for both the healthy population and specific patient groups.



One reason for this is that it is not clear what the extent of the variation in response to very long-chain *n*-3 fatty acids is within the population or amongst particular sub-groups, or what the determinants of such variation might be, although these are likely to include other dietary components, sex, body composition, genetics, stage in the life course, physiological state and the presence of disease. These determinants are likely to be more thoroughly explored in the coming years, with researchers taking advantage of new analytical and data handling technologies to study larger numbers of samples. Surprisingly, there is insufficient information currently available on dose responses of many physiological and pathological outcomes to very long-chain *n*-3 fatty acid intervention. This hampers the ability to use the full potential of very long-chain *n*-3 fatty acids in both public health and clinical settings. Most research on very long-chain *n*-3 fatty acids to date has focused on EPA and DHA, usually studied in combination. This has resulted in many researchers thinking that EPA and DHA have the same biological effects. This seems not to be the case<sup>(268,269)</sup>, but again this is an area of research that is likely to become better explored in the next period. Related to this, biological actions of DPA have emerged<sup>(4,5)</sup> but the effects of DPA and its mechanisms of action are poorly described at the moment. It seems likely that DPA will become a greater focus of research in this area. It is also likely that research into the molecular mechanisms of the action of each individual very long-chain *n*-3 fatty acid will continue, with membrane structure–function relationships, early intracellular signalling pathways, transcription factors, novel membrane receptors and novel lipid mediators all being important candidates for future study. Whatever the mechanism involved, it is evident that EPA, DPA and DHA consumed orally need to be found at the site of their action in the body. As described earlier, it is also clear that the effects of these fatty acids on cell and tissue function are dose dependent<sup>(39,40,42,45)</sup>. Thus, it seems likely that strategies for more effective delivery of these bioactive fatty acids will be explored. These might include different chemical<sup>(270,271)</sup> or physical<sup>(272)</sup> formulations.

The richest dietary source of very long-chain *n*-3 fatty acids is seafood, especially fatty fish (Table 1). Despite recommendations by many authorities to increase consumption of fish, the majority of the Western population are low consumers. An alternative to eating fish is to use *n*-3 supplements (fish oil) which give an assured intake of EPA and DHA. A concern is that the supply of fish for human consumption and for the production of oil for use in *n*-3 supplements is not sustainable. Thus, alternative sources need to be sought and then proven to be beneficial to human health. Such alternatives include algal oils, some of which are already widely used in the infant formula industry and seed oils from plants GM to produce EPA and DHA<sup>(273)</sup>. Finally, although the focus of the present paper is the very long-chain *n*-3 fatty acids EPA, DPA and DHA, plant *n*-3 fatty acids are widely available and are sustainable. Most research on plant *n*-3 fatty acids conducted to date has been on ALA as an alternative to very long-chain *n*-3 fatty acids<sup>(8)</sup>, but

there has been some research on SDA<sup>(8,274)</sup>. From the research conducted to date, ALA and SDA need to be converted to very long-chain *n*-3 fatty acids by the pathway shown in Fig. 1 to be biologically effective<sup>(8)</sup>. However, the studies done so far show very poor conversion of ALA and SDA to DHA in human subjects, although SDA is a better precursor for EPA synthesis than ALA<sup>(275)</sup>. Future research will attempt to identify strategies to enhance endogenous biosynthesis of very long-chain *n*-3 fatty acids from their simpler plant precursors. These strategies might include modifying other aspects of the diet or taking advantage of genetic polymorphisms that favour conversion. Thus, there are many important questions yet to be answered and this assures continued research in the field of *n*-3 fatty acids and human health.

### Summary and conclusions

*n*-3 Fatty acids are a family of PUFA that contribute to human development, health and well-being. Functionally the most important *n*-3 fatty acids are the very long-chain EPA and DHA found in fatty fish and in supplements; roles for DPA are now emerging. Intakes of EPA and DHA are typically low and much below those that are recommended. Increased intakes of EPA and DHA, either from fish or from supplements, are reflected in greater incorporation into blood lipid, cell and tissue pools. Increased content of EPA and DHA can modify the structure of cell membranes and also the function of membrane proteins involved as receptors, signalling proteins, transporters and enzymes. EPA and DHA also modify the production of lipid mediators and through effects on cell signalling can alter patterns of gene expression. Through these actions EPA and DHA act to alter cellular responsiveness in a manner that seems to result in more optimal conditions for growth, development and maintenance of health. The effects of very long-chain *n*-3 fatty acids are evident right through the life course meaning that there is a need for all sectors of the population to increase the intake of these important nutrients. EPA and DHA have a wide range of physiological roles, which are linked to certain health or clinical benefits. A number of risk factors for CVD are modified in a beneficial way by increased intake of EPA and DHA; these include blood pressure, platelet reactivity and thrombosis, plasma TAG concentrations, vascular function, cardiac arrhythmias, heart rate variability and inflammation. Thus, there is a key role for these fatty acids in prevention and slowing progression of CVD. Furthermore, some supplementation studies with EPA and DHA have demonstrated reduced mortality in at risk patients, such as post-MI, indicating a therapeutic role, although this is currently disputed by some. A number of other, non-cardiovascular, actions of EPA and DHA have also been documented, suggesting that increased intake of these fatty acids could be of benefit in reducing the risk of (i.e. protecting from) or treating many conditions. For example, they have been used successfully in RA and, in some studies, in inflammatory

bowel disease, and may be useful in other inflammatory conditions like asthma and psoriasis. EPA and DHA may also have a role as part of cancer therapy; some recent studies show that they improve the effectiveness of chemotherapeutic agents. DHA has an important structural role in the eye and brain, and its supply early in life when these tissues are developing is known to be of importance in terms of optimising visual and neurological development. For this reason it is very important that pregnant and breast-feeding women have adequate DHA intake. Recent studies have highlighted the potential for EPA and DHA to contribute to enhanced mental development and improved childhood learning and behaviour and to reduce the burden of psychiatric and depressive illnesses in adults, although these areas of possible action require more robust scientific support. There may also be a role for EPA and DHA in preventing neurodegenerative disease of ageing, but evidence for this is currently weak. The effects of EPA and DHA on health outcomes are likely to be dose-dependent, but clear dose-response data have not been identified in most cases. Also in many cases it is not clear whether both EPA and DHA have the same effect or potency and therefore which one will be the most important for a particular indication. Thus, despite several decades of productive research on the health effects of very long-chain *n*-3 fatty acids and the mechanisms involved, important questions are currently unanswered and many areas remain to be explored in future research.

#### Conflict of interest

The author serves on the Scientific Advisory Boards of Pronova BioPharma (part of BASF), Smartfish, DSM, FrieslandCampina and Danone Nutricia Research.

#### Financial Support

None.

#### Authorship

The author had sole responsibility for all aspects of preparation of this paper.

#### References

- Burdge GC & Calder PC (2015) Introduction to fatty acids and lipids. *World Rev Nutr Diet* **112**, 1–16.
- Calder PC & Yaquob P (2009) Understanding omega-3 polyunsaturated fatty acids. *Postgrad Med* **121**, 148–157.
- Calder PC (2014) Very long chain omega-3 (*n*-3) fatty acids and human health. *Eur J Lipid Sci Technol* **116**, 1280–1300.
- Kaur G, Cameron-Smith D, Garg M *et al.* (2011) Docosapentaenoic acid (22:5n-3): a review of its biological effects. *Prog Lipid Res* **50**, 28–34.
- Weylandt KH (2016) Docosapentaenoic acid derived metabolites and mediators – the new world of lipid mediator medicine in a nutshell. *Eur J Pharmacol* **785**, 108–115.
- Blasbalg TL, Hibbeln JR, Ramsden CE *et al.* (2011) Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. *Am J Clin Nutr* **93**, 950–962.
- Arterburn LM, Hall EB & Oken H (2006) Distribution, interconversion, and dose response of *n*-3 fatty acids in humans. *Am J Clin Nutr* **83**, 1467S–1476S.
- Baker EJ, Miles EA, Burdge GC *et al.* (2016) Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. *Prog Lipid Res* **64**, 30–56.
- Bolton-Smith C, Woodward M & Tavendale R (1997) Evidence for age-related differences in the fatty acid composition of human adipose tissue, independent of diet. *Eur J Clin Nutr* **51**, 619–624.
- Childs CE, Romeu-Nadal M, Burdge GC *et al.* (2008) Gender differences in the *n*-3 fatty acid content of tissues. *Proc Nutr Soc* **67**, 19–27.
- Burdge GC, Jones AE & Wootton SA (2002) Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men. *Brit J Nutr* **88**, 355–363.
- Burdge GC & Wootton SA (2002) Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. *Brit J Nutr* **88**, 411–420.
- Vessby B, Gustafsson IB, Tengblad S *et al.* (2002) Desaturation and elongation of fatty acids and insulin action. *Ann NY Acad Sci* **967**, 183–195.
- Koletzko B, Lattka E, Zeilinger S *et al.* (2011) Genetic variants of the fatty acid desaturase gene cluster predict amounts of red blood cell docosahexaenoic acid and other polyunsaturated fatty acids in pregnant women: findings from the Avon Longitudinal Study of Parents and Children. *Am J Clin Nutr* **93**, 211–219.
- British Nutrition Foundation (1999) *N-3 Fatty Acids and Health*. London: British Nutrition Foundation.
- Calder PC (2017) Omega-3: the good oil. *Nutr Bull* **42**, 132–140.
- Scientific Advisory Committee on Nutrition/Committee on Toxicity (2004) *Advice on Fish Consumption: Benefits and Risks*. London: TSO.
- Meyer BJ, Mann NJ, Lewis JL *et al.* (2003) Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. *Lipids* **38**, 391–398.
- Howe P, Meyer B, Record S *et al.* (2006) Dietary intake of long-chain omega-3 polyunsaturated fatty acids: contribution of meat sources. *Nutrition* **22**, 47–53.
- Rahmawaty S, Charlton K, Lyons-Wall P *et al.* (2013) Dietary intake and food sources of EPA, DPA and DHA in Australian children. *Lipids* **48**, 869–877.
- Stubbs CD & Smith AD (1984) The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. *Biochim Biophys Acta* **779**, 89–137.
- Brenner RR (1984) Effect of unsaturated fatty acids on membrane structure and enzyme kinetics. *Prog Lipid Res* **23**, 69–96.
- Murphy MG (1990) Dietary fatty acids and membrane protein function. *J Nutr Biochem* **1**, 68–79.
- Browning LM, Walker CG, Mander AP *et al.* (2012) Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. *Am J Clin Nutr* **96**, 748–758.



25. Miles EA, Noakes PS, Kremmyda LS *et al.* (2011) The Salmon in Pregnancy Study: study design, subject characteristics, maternal fish and marine n-3 fatty acid intake, and marine n-3 fatty acid status in maternal and umbilical cord blood. *Am J Clin Nutr* **94**, 1986S–1992S.
26. Healy DA, Wallace FA, Miles EA *et al.* (2000) The effect of low to moderate amounts of dietary fish oil on neutrophil lipid composition and function. *Lipids* **35**, 763–768.
27. Skinner ER, Watt C, Besson JA *et al.* (1993) Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. *Brain* **116**, 717–725.
28. Makrides M, Neumann MA, Byard RW *et al.* (1994) Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. *Am J Clin Nutr* **60**, 189–194.
29. Harris WS, Sands SA, Windsor SL *et al.* (2004) Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. *Circulation* **110**, 1645–1649.
30. Metcalf RG, James MJ, Gibson RA *et al.* (2007) Effects of fish-oil supplementation on myocardial fatty acids in humans. *Am J Clin Nutr* **85**, 1222–1228.
31. McGlory C, Galloway SD, Hamilton DL *et al.* (2014) Temporal changes in human skeletal muscle and blood lipid composition with fish oil supplementation. *Prostaglandin Leukotriene Essent Fatty Acids* **90**, 199–206.
32. Smith GI, Atherton P, Reeds DN *et al.* (2011) Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women. *Clin Sci* **121**, 267–278.
33. Araya J, Rodrigo R, Videla LA *et al.* (2004) Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. *Clin Sci* **106**, 635–643.
34. Elizondo A, Araya J, Rodrigo R *et al.* (2007) Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. *Obesity* **15**, 24–31.
35. Hillier K, Jewell R, Dorrell L *et al.* (1991) Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. *Gut* **32**, 1151–1155.
36. Safarinejad MR (2011) Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. *Andrologia* **43**, 38–47.
37. Crawford MA, Casperd NM & Sinclair AJ (1976) The long chain metabolites of linoleic and linolenic acids in liver and brain in herbivores and carnivores. *Comp Biochem Physiol* **54B**, 395–401.
38. Anderson RE (1970) Lipids of ocular tissues. IV. A comparison of the phospholipids from the retina of six mammalian species. *Exp Eye Res* **10**, 339–344.
39. von Schacky C, Fischer S & Weber PC (1985) Long term effects of dietary marine  $\omega$ -3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. *J Clin Invest* **76**, 1626–1631.
40. Harris WS, Windsor SL & Dujovne CA (1991) Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. *J Am Coll Nutr* **10**, 220–227.
41. Marsen TA, Pollok M, Oette K *et al.* (1992) Pharmacokinetics of omega-3 fatty acids during ingestion of fish oil preparations. *Prostaglandin Leukotriene Essent Fatty Acids* **46**, 191–196.
42. Blonk MC, Bilo HJ, Popp-Snijders C *et al.* (1990) Dose-response effects of fish oil supplementation in healthy volunteers. *Am J Clin Nutr* **52**, 120–127.
43. Katan MB, Deslypere JP, van Birgelen APJM *et al.* (1997) Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes and adipose tissue: an 18 month controlled study. *J Lipid Res* **38**, 2012–2022.
44. Yaqoob P, Pala HS, Cortina-Borja M *et al.* (2000) Encapsulated fish oil enriched in  $\alpha$ -tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions. *Eur J Clin Invest* **30**, 260–274.
45. Rees D, Miles EA, Banerjee T *et al.* (2006) Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. *Am J Clin Nutr* **83**, 331–342.
46. Faber J, Berkhout M, Vos AP *et al.* (2011) Supplementation with a fish oil-enriched, high-protein medical food leads to rapid incorporation of EPA into white blood cells and modulates immune responses within one week in healthy men and women. *J Nutr* **141**, 964–970.
47. Popp-Snijders C, Schouten JA, van Blitterswijk WJ *et al.* (1986) Changes in membrane lipid composition of human erythrocytes after dietary supplementation of (n-3) fatty acids: maintenance of membrane fluidity. *Biochim Biophys Acta* **854**, 31–37.
48. Sanders TAB & Roshanai F (1983) The influence of different types of  $\omega$ 3 polyunsaturated fatty acids on blood lipids and platelet function in healthy volunteers. *Clin Sci* **64**, 91–99.
49. Sperling RI, Benincaso AI, Knoell CT *et al.* (1993) Dietary  $\omega$ -3 polyunsaturated fatty acids inhibit phosphoinositide formation, and chemotaxis in neutrophils. *J Clin Invest* **91**, 651–660.
50. Sorensen LS, Rasmussen HH, Aardestrup IV *et al.* (2014) Rapid incorporation of  $\omega$ -3 fatty acids into colonic tissue after oral supplementation in patients with colorectal cancer: a randomized, placebo-controlled intervention trial. *J Parent Ent Nutr* **38**, 617–624.
51. Calder PC (2012) Mechanisms of action of (n-3) fatty acids. *J Nutr* **142**, 592S–599S.
52. Calder PC (2013) Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? *Brit J Clin Pharmacol* **75**, 645–662.
53. Calder PC (2013) n-3 Fatty acids, inflammation and immunity: new mechanisms to explain old actions. *Proc Nutr Soc* **72**, 326–336.
54. Calder PC, Yaqoob P, Harvey DJ *et al.* (1994) The incorporation of fatty acids by lymphocytes and the effect on fatty acid composition and membrane fluidity. *Biochem J* **300**, 509–518.
55. Miles EA & Calder PC (1998) Modulation of immune function by dietary fatty acids. *Proc Nutr Soc* **57**, 277–292.
56. Niu SL, Mitchell DC, Lim SY *et al.* (2004) Reduced G protein-coupled signaling efficiency in retinal rod outer segments in response to n-3 fatty acid deficiency. *J Biol Chem* **279**, 31098–31104.
57. Pike LJ (2003) Lipid rafts: bringing order to chaos. *J Lipid Res* **44**, 655–667.
58. Simons K & Gerl MJ (2010) Revitalizing membrane rafts: new tools and insights. *Nat Rev Mol Cell Biol* **11**, 688–699.
59. Yaqoob P (2009) The nutritional significance of lipid rafts. *Annu Rev Nutr* **29**, 257–282.
60. Calder PC & Yaqoob P (2007) Lipid rafts – Composition, characterization and controversies. *J Nutr* **137**, 545–547.



61. Hou TY, McMurray DN & Chapkin RS (2016) Omega-3 fatty acids, lipid rafts, and T cell signaling. *Eur J Pharmacol* **785**, 2–9.
62. Calder PC (2013) Fat chance to enhance B cell function. *J Leuk Biol* **93**, 457–459.
63. Calder PC (2013) Long chain fatty acids and gene expression in inflammation and immunity. *Curr Opin Clin Nutr Metab Care* **16**, 425–433.
64. Novak TE, Babcock TA, Jho DH *et al.* (2003) NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. *Am J Physiol* **284**, L84–L89.
65. Krey G, Braissant O, L'Horset F *et al.* (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. *Mol Endocrinol* **11**, 779–791.
66. Marion-Letellier R, Savoye G & Ghosh S (2016) Fatty acids, eicosanoids and PPAR gamma. *Eur J Pharmacol* **785**, 44–49.
67. Clarke SD (2004) The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. *Curr Opin Lipidol* **15**, 13–18.
68. Lapillonne A, Clarke SD & Heird WC (2004) Polyunsaturated fatty acids and gene expression. *Curr Opin Clin Nutr Metab Care* **7**, 151–156.
69. Jump DB (2002) Dietary polyunsaturated fatty acids and regulation of gene transcription. *Curr Opin Lipidol* **13**, 155–1564.
70. Jump DB (2008) N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. *Curr Opin Lipidol* **19**, 242–247.
71. Deckelbaum RJ, Worgall TS & Seo T (2006) N-3 fatty acids and gene expression. *Am J Clin Nutr* **83**, 1520S–1525S.
72. Calder PC (2011) Fatty acids and inflammation: the cutting edge between food and pharma. *Eur J Pharmacol* **668**, S50–S58.
73. Lewis RA, Austen KF & Soberman RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. *N Engl J Med* **323**, 645–655.
74. Tilley SL, Coffman TM & Koller BH (2001) Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. *J Clin Invest* **108**, 15–23.
75. Wada M, DeLong CJ, Hong YH *et al.* (2007) Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. *J Biol Chem* **282**, 22254–22266.
76. Moncada S & Vane JR (1979) The role of prostacyclin in vascular tissue. *Fed Proc* **38**, 68–71.
77. Bannenberg G & Serhan CN (2010) Specialized pro-resolving lipid mediators in the inflammatory response: an update. *Biochim Biophys Acta Mol Cell Biol Lipids* **1801**, 1260–1273.
78. Serhan CN, Chiang N & van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. *Nat Rev Immunol* **8**, 349–361.
79. Serhan CN & Chiang N (2013) Resolution phase lipid mediators of inflammation: agonists of resolution. *Curr Opin Pharmacol* **13**, 632–640.
80. Dalli J, Colas RA & Serhan CN (2013) Novel n-3 immunoresolvents: structures and roles. *Sci Rep* **3**, 1940.
81. Calder PC (2015) Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. *Biochim Biophys Acta* **1851**, 469–484.
82. Oh DY, Talukdar S, Bae EJ *et al.* (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell* **142**, 687–698.
83. Dyerberg J, Bang HO, Stoffersen E *et al.* (1978) Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. *Lancet* **ii**, 117–119.
84. Kromann N & Green A (1980) Epidemiological studies in the Upernavik District, Greenland. *Acta Med Scand* **208**, 401–406.
85. Bjerregaard P & Dyerberg J (1988) Mortality from ischemic heart disease and cerebrovascular disease in Greenland. *Int J Epidemiol* **17**, 514–519.
86. Newman WP, Middaugh JP, Propst MT *et al.* (1993) Atherosclerosis in Alaska Natives and non-natives. *Lancet* **341**, 1056–1057.
87. Bang HO, Dyerberg J & Hjorne N (1976) The composition of foods consumed by Greenland Eskimos. *Acta Med Scand* **200**, 69–73.
88. Yano K, MacLean CJ, Reed DM *et al.* (1988) A comparison of the 12-year mortality and predictive factors of coronary heart disease among Japanese men in Japan and Hawaii. *Am J Epidemiol* **127**, 476–487.
89. Kris-Etherton PM, Harris WS & Appel LJ (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. American Heart Association Nutrition Committee. *Circulation* **106**, 2747–2757.
90. von Schacky C (2004) Omega-3 fatty acids and cardiovascular disease. *Curr Opin Clin Nutr Metab Care* **7**, 131–136.
91. London B, Albert C, Anderson M *et al.* (2007) Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. *Circulation* **116**, e320–e335.
92. Wang C, Harris WS, Chung M *et al.* (2006) n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. *Am J Clin Nutr* **84**, 5–17.
93. Calder PC (2004) n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. *Clin Sci* **107**, 1–11.
94. Chowdhury R, Warnakula S, Kunutsor S *et al.* (2014) Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. *Ann Intern Med* **160**, 398–406.
95. Del Gobbo LC, Imamura F, Aslibekyan S *et al.* (2016) ω-3 Polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies. *JAMA Intern Med* **176**, 1155–1166.
96. Calder PC (2017) New evidence that omega-3 fatty acids have a role in primary prevention of coronary heart disease. *J Pub Health Emerg* **1**, 35.
97. Harris WS (1996) N-3 fatty acids and lipoproteins: comparison of results from human and animal studies. *Lipids* **31**, 243–252.
98. Saravanan P, Davidson NC, Schmidt EB *et al.* (2010) Cardiovascular effects of marine omega-3 fatty acids. *Lancet* **376**, 540–550.
99. De Caterina R (2011) n-3 fatty acids in cardiovascular disease. *N Engl J Med* **364**, 2439–2450.
100. Balk EM, Lichtenstein AH, Chung M *et al.* (2006) Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. *Atherosclerosis* **189**, 19–30.

101. Leslie MA, Cohen DJ, Liddle DM *et al.* (2015) A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals. *Lipids Health Dis* **14**, 53.
102. AbuMweis S, Jew S, Tayyem R *et al.* (2017) Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. *J Hum Nutr Diet* (In the Press).
103. Mori TA, Burke V, Puddey IB *et al.* (2000) Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. *Am J Clin Nutr* **71**, 1085–1094.
104. Burr ML, Fehily AM, Gilbert JF *et al.* (1989) Effects of changes in fat, fish and fibre intake on death and myocardial reinfarction: diet and reinfarction trial (DART). *Lancet* **ii**, 757–761.
105. Anonymous (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. *Lancet* **354**, 447–455.
106. Marchioli R, Barzi F, Bomba E *et al.* (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction - Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation* **105**, 1897–1903.
107. Yokoyama M, Origasa H, Matsuzaki M *et al.* (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet* **369**, 1090–1098.
108. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R *et al.* (2008). Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* **372**, 1223–1230.
109. Bucher HC, Hengstler P, Schindler C *et al.* (2002) N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. *Am J Med* **112**, 298–304.
110. Studer M, Briel M, Leimenstoll B *et al.* (2005) Effect of different antilipidemic agents and diets on mortality: a systematic review. *Arch Intern Med* **165**, 725–730.
111. Leon H, Shibata MC, Sivakumaran S *et al.* (2009) Effect of fish oil on arrhythmias and mortality: systematic review. *Brit Med J* **338**, a2931.
112. Harris WS, Miller M, Tighe AP *et al.* (2008) Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. *Atherosclerosis* **197**, 12–24.
113. Xin W, Wei W & Li XY (2013) Short-term effects of fish-oil supplementation on heart rate variability in humans: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* **97**, 926–935.
114. Leaf A & Xiao YF (2001) The modulation of ionic currents in excitable tissues by n-3 polyunsaturated fatty acids. *J Memb Biol* **184**, 263–271.
115. Thies F, Garry JMC, Yaquob P *et al.* (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. *Lancet* **361**, 477–485.
116. Cawood AL, Ding R, Napper FL *et al.* (2010) Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. *Atherosclerosis* **212**, 252–259.
117. Calder PC & Yaquob P (2010) Omega-3 (n-3) fatty acids, cardiovascular disease and stability of atherosclerotic plaques. *Cell Mol Biol* **56**, 28–37.
118. Galan P, Kesse-Guyot E, Czernichow S *et al.* (2010) Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. *BMJ* **341**, c6273.
119. Kromhout D, Giltay EJ, Geleijnse JM *et al.* (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. *N Engl J Med* **363**, 2015–2026.
120. Rauch B, Schiele R, Schneider S *et al.* (2010) OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. *Circulation* **122**, 2152–2159.
121. Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M, Avanzini F *et al.* (2013) n-3 fatty acids in patients with multiple cardiovascular risk factors. *N Engl J Med* **368**, 1800–1808.
122. Bosch J, Gerstein HC, Dagenais GR *et al.* (2012) n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *N Engl J Med* **367**, 309–318.
123. Kwak SM, Myung SK, Lee YJ *et al.* (2012) Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Arch Intern Med* **172**, 686–694.
124. Kotwal S, Jun M, Sullivan D *et al.* (2012) Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. *Circ Cardiovasc Qual Outcomes* **5**, 808–818.
125. Rizos EC, Ntzani EE, Bika E *et al.* (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. *J Am Med Assoc* **308**, 1024–1033.
126. Calder PC & Yaquob P (2012) Marine omega-3 fatty acids and coronary heart disease. *Curr Opin Cardiol* **27**, 412–419.
127. Casula M, Soranna D, Catapano AL *et al.* (2013) Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, double blind, placebo controlled trials. *Atheroscler Suppl* **14**, 243–251.
128. Wen YT, Dai JH & Gao Q (2014) Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. *Nutr Metab Cardiovasc Dis* **24**, 470–475.
129. Siscovick DS, Barringer TA, Fretts AM *et al.* (2017) Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. *Circulation* **135**, e867–e884.
130. Gleissman H, Johnsen JI & Kogner P (2010) Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? *Exp Cell Res* **316**, 1365–1373.
131. Merendino N, Costantini L, Manzi L *et al.* (2013) Dietary ω-3 polyunsaturated fatty acids DHA: a potential adjuvant in the treatment of cancer. *BioMed Res Int* **2013**; 310186.
132. Wang D & Dubois RN (2010) Eicosanoids and cancer. *Nat Rev Cancer* **10**, 181–193.
133. Vaughan VC, Hassing MR & Lewandowski PA (2013) Marine polyunsaturated fatty acids and cancer therapy. *Brit J Cancer* **108**, 486–492.



134. Murphy RA, Mourtzakis M & Mazurak VC (2012) n-3 polyunsaturated fatty acids: the potential role for supplementation in cancer. *Curr Opin Clin Nutr Metab Care* **15**, 246–251.
135. Yang B, Wang FL, Ren XL *et al.* (2014) Biospecimen long-chain n-3 PUFA and risk of colorectal cancer: a meta-analysis of data from 60,627 individuals. *PLoS ONE* **9**, e110574.
136. Makarem N, Chandran U, Bandera EV *et al.* (2013) Dietary fat in breast cancer survival. *Annu Rev Nutr* **33**, 319–348.
137. Sczaniecka AK, Brasky TM, Lampe JW *et al.* (2012) Dietary intake of specific fatty acids and breast cancer risk among postmenopausal women in the VITAL cohort. *Nutr Cancer* **64**, 1131–1142.
138. Brasky TM, Darke AK, Song X *et al.* (2013) Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. *J Natl Cancer Inst* **105**, 1132–1141.
139. Crowe FL, Appleby PN, Travis RC *et al.* (2014) Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. *J Natl Cancer Inst* **106**, dju240.
140. Elia M, Van Bokhorst-de van der Schueren MA, Garvey J *et al.* (2006) Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. *Int J Oncol* **28**, 5–23.
141. Alfano CM, Imayama I, Neuhouser ML *et al.* (2012) Fatigue, inflammation, and  $\omega$ -3 and  $\omega$ -6 fatty acid intake among breast cancer survivors. *J Clin Oncol* **30**, 1280–1287.
142. Cerchietti LC, Navigante AH & Castro MA (2007) Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. *Nutr Cancer* **59**, 14–20.
143. van der Meij BS, Langius JA, Spreeuwenberg MD *et al.* (2012) Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT. *Eur J Clin Nutr* **66**, 399–404.
144. Sala-Vila A, Folkes J & Calder PC (2010) The effect of three lipid emulsions differing in fatty acid composition on growth, apoptosis and cell cycle arrest in the HT-29 colorectal cancer cell line. *Clin Nutr* **29**, 519–524.
145. Murphy RA, Mourtzakis M, Chu QS *et al.* (2011) Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. *Cancer* **117**, 3774–3780.
146. Bougnoux P, Hajjaji N, Ferrasson MN *et al.* (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. *Brit J Cancer* **101**, 1978–1985.
147. Weed HG, Ferguson ML, Gaff RL *et al.* (2011) Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein- and energy-dense nutritional supplement containing eicosapentaenoic acid. *Head Neck* **33**, 1027–1033.
148. Murphy RA, Mourtzakis M, Chu QS *et al.* (2011) Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. *Cancer* **117**, 1775–1782.
149. Fearon KC, Barber MD, Moses AG *et al.* (2006) Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. *J Clin Oncol* **24**, 3401–3407.
150. Guarcello M, Riso S, Buosi R *et al.* (2007) EPA-enriched oral nutritional support in patients with lung cancer: effects on nutritional status and quality of life. *Nutr Therap Metab* **25**, 25–30.
151. Calder PC, Albers R, Antoine JM *et al.* (2009) Inflammatory disease processes and interactions with nutrition. *Brit J Nutr* **101**, Suppl. 1, S1–45.
152. Calder PC, Ahluwalia N, Albers R *et al.* (2013) A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies. *Brit J Nutr* **109**, Suppl. 1, S1–S34.
153. Ross R (1999) Atherosclerosis--an inflammatory disease. *N Engl J Med* **340**, 115–126.
154. Hansson GK & Hermansson A (2011) The immune system in atherosclerosis. *Nat Immunol* **12**, 204–212.
155. Calder PC, Ahluwalia N, Brouns F *et al.* (2011) Dietary factors and low-grade inflammation in relation to overweight and obesity. *Brit J Nutr* **106**, Suppl. 3, S5–S78.
156. Colotta F, Allavena P, Sica A *et al.* (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis* **30**, 1073–1081.
157. Miles EA & Calder PC (2012) Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. *Brit J Nutr* **107**, Suppl. 2, S171–S184.
158. Calder PC (2009) Fatty acids and immune function: relevance to inflammatory bowel diseases. *Int Rev Immunol* **28**, 506–534.
159. Calder PC (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. *Am J Clin Nutr* **83**, 1505S–1519S.
160. Abdulrazaq M, Innes JK & Calder PC (2017) Effect of  $\omega$ -3 polyunsaturated fatty acids on arthritic pain: a systematic review. *Nutrition* **39–40**, 57–66.
161. Senftleber NK, Nielsen SM, Andersen JR *et al.* (2017) Marine oil supplements for arthritis pain: a systematic review and meta-analysis of randomized trials. *Nutrients* **9**, 42.
162. Calder PC, Kremmyda LS, Vlachava M *et al.* (2010) Is there a role for fatty acids in early life programming of the immune system? *Proc Nutr Soc* **69**, 373–380.
163. Dunstan JA, Mori TA, Barden A *et al.* (2003) Maternal fish oil supplementation in pregnancy reduces interleukin-13 levels in cord blood of infants at high risk of atopy. *Clin Exp Allergy* **33**, 442–448.
164. Dunstan JA, Mori TA, Barden A *et al.* (2003) Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. *J Allergy Clin Immunol* **112**, 1178–1184.
165. Noakes PS, Vlachava M, Kremmyda LS *et al.* (2012) Increased intake of oily fish in pregnancy: effects on neonatal immune responses and on clinical outcomes in infants at 6 mo. *Am J Clin Nutr* **95**, 395–404.
166. Furuholm C, Warstedt K, Larsson J *et al.* (2009) Fish oil supplementation in pregnancy and lactation may decrease the risk of infant allergy. *Acta Paediatr* **98**, 1461–1467.
167. Palmer DJ, Sullivan T, Gold MS *et al.* (2012) Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: randomised controlled trial. *Brit Med J* **344**, e184.
168. Best KP, Gold M, Kennedy D *et al.* (2016) Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: a systematic review and meta-analysis of observational studies and randomized controlled trials. *Am J Clin Nutr* **103**, 128–143.



169. Bisgaard H, Stokholm J, Chawes BL *et al.* (2016) Fish oil-derived fatty acids in pregnancy and wheeze and asthma in offspring. *N Engl J Med* **375**, 2530–2539.
170. D'Vaz N, Meldrum SJ, Dunstan JA *et al.* (2012) Fish oil supplementation in early infancy modulates developing infant immune responses. *Clin Exp Allergy* **42**, 1206–1216.
171. Willemsen LEM (2016) Dietary n-3 long chain polyunsaturated fatty acids in allergy prevention and asthma treatment. *Eur J Pharmacol* **785**, 174–186.
172. Klemens CM, Berman DR & Mozurkewich EL (2011) The effect of perinatal omega-3 fatty acid supplementation on inflammatory markers and allergic disease: a systematic review. *Brit J Obstet Gynaecol* **118**, 916–925.
173. Miles EA & Calder PC (2017) Can early omega-3 fatty acid exposure reduce risk of childhood allergic disease? *Nutrients* **9**, 784.
174. Lauritzen L, Hansen HS, Jorgensen MH *et al.* (2001) The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. *Prog Lipid Res* **40**, 1–94.
175. Salem N, Litman B, Kim HY *et al.* (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. *Lipids* **36**, 945–959.
176. Parletta N, Milte CM & Meyer BJ (2013) Nutritional modulation of cognitive function and mental health. *J Nutr Biochem* **24**, 725–743.
177. Uauy RD, Birch DG, Birch EE *et al.* (1990) Effect of dietary omega-3 fatty acids on retinal function of very-low-birth-weight neonates. *Pediatr Res* **28**, 485–492.
178. Birch DG, Birch EE, Hoffman DR *et al.* (1992) Retinal development in very-low-birth-weight infants fed diets differing in omega-3 fatty acids. *Invest Ophthalmol Vis Sci* **33**, 2365–2376.
179. Birch EE, Birch DG, Hoffman DR *et al.* (1992) Dietary essential fatty acid supply and visual acuity development. *Invest Ophthalmol Vis Sci* **33**, 3242–3253.
180. Carlson SE, Werkman SH, Rhodes PG *et al.* (1993) Visual acuity development in healthy preterm infants: effect of marine oil supplementation. *Am J Clin Nutr* **58**, 35–42.
181. Carlson SE, Ford AJ, Werkman SH *et al.* (1996) Visual acuity and fatty acid status of term infants fed human milk and formulas with and without docosahexaenoate and arachidonate from egg yolk lecithin. *Pediatr Res* **39**, 882–888.
182. Carlson SE, Werkman SH & Tolley EA (2000) Effect of long-chain n-3 fatty acid supplementation on visual acuity and growth of preterm infants with and without bronchopulmonary dysplasia. *Am J Clin Nutr* **63**, 687–697.
183. Moon K, Rao SC, Schulzke SM *et al.* (2016) Long-chain polyunsaturated fatty acid supplementation in preterm infants. *Cochrane Database Syst Rev* **12**, CD000375.
184. Molloy C, Doyle LW, Makrides M *et al.* (2012) Docosahexaenoic acid and visual functioning in preterm infants: a review. *Neuropsychol Rev* **22**, 425–437.
185. Agostoni C, Trojan S, Bellu R *et al.* (1995) Neurodevelopmental quotient of healthy term infants at 4 months and feeding practice: the role of long-chain polyunsaturated fatty acids. *Pediatr Res* **38**, 262–266.
186. Willatts P, Forsyth JS, DiModugno MK *et al.* (1998) Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age. *Lancet* **352**, 688–691.
187. Scott DT, Janowsky JS, Carroll RE *et al.* (1998) Formula supplementation with long-chain polyunsaturated fatty acids: are there developmental benefits? *Pediatrics* **102**, E59.
188. Makrides M, Neumann MA, Simmer K *et al.* (2000) A critical appraisal of the role of dietary long-chain polyunsaturated fatty acids on neural indices of term infants: a randomized, controlled trial. *Pediatrics* **105**, 32–38.
189. Auested N, Halter R, Hall RT *et al.* (2001) Growth and development of term infants fed long-chain polyunsaturated fatty acids: a double-masked, randomized, parallel, prospective, multivariate study. *Pediatrics* **108**, 272–381.
190. Auested N, Scott DT, Janowsky JS *et al.* (2003) Visual, cognitive, and language assessments at 39 months: a follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. *Pediatrics* **112**, e177–e183.
191. Agostoni C, Trojan S, Bellu R *et al.* (1997) Developmental quotient at 24 months and fatty acid composition of diet in early infancy: a follow up study. *Arch Dis Child* **1997**, 76, 421–424.
192. Jasani B, Simmer K, Patole SK *et al.* (2017) Long chain polyunsaturated fatty acid supplementation in infants born at term. *Cochrane Database Syst Rev* **3**, CD000376.
193. Gould JF, Smithers LG & Makrides M (2013) The effect of maternal omega-3 (n-3) LCPUFA supplementation during pregnancy on early childhood cognitive and visual development; a systematic review and meta-analysis of randomized controlled trials. *Am J Clin Nutr* **97**, 531–544.
194. Richardson AJ (2004) Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. *Prostaglandin Leuk Essent Fatty Acids* **70**, 383–390.
195. Stevens L, Zhang W, Peck L *et al.* (2003) EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. *Lipids* **38**, 1007–1021.
196. Richardson AJ & Puri BK (2002) A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. *Prog Neuropsychopharmacol Biol Psych* **26**, 233–239.
197. Yui K, Koshiba M, Nakamura S *et al.* (2012) Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial. *J Clin Psychopharmacol* **32**, 200–206.
198. Meguid NA, Atta HM, Gouda AS *et al.* (2008) Role of polyunsaturated fatty acids in the management of Egyptian children with autism. *Clin Biochem* **41**, 1044–1048.
199. Perera H, Jeewandara KC, Seneviratne S *et al.* (2012) Combined  $\omega$ 3 and  $\omega$ 6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. *J Child Neurol* **27**, 747–753.
200. Milte CM, Parletta N, Buckley JD *et al.* (2012) Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. *Nutrition* **28**, 670–677.
201. Gustafsson PA, Birberg-Thornberg U, Duchén K *et al.* (2010) EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. *Acta Paediatr* **99**, 1540–1549.
202. Bélanger SA, Vanasse M, Spahis S *et al.* (2009) Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. *Paediatr Child Health* **14**, 89–98.
203. Sorgi PJ, Hallowell EM, Hutchins HL *et al.* (2007) Effects of an open-label pilot study with high-dose EPA/DHA

- concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. *Nutr J* **6**, 16.
204. Bos DJ, Oranje B, Veerhoek ES *et al.* (2015) Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. *Neuropsychopharmacol* **40**, 2298–2306.
205. Sheppard KW, Boone KM, Gracious B *et al.* (2017) Effect of omega-3 and -6 supplementation on language in preterm toddlers exhibiting autism spectrum disorder symptoms. *J Autism Dev Disord* (In the Press).
206. Voigt RG, Llorente AM, Jensen CL *et al.* (2001) A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. *J Pediatr* **139**, 189–196.
207. Hirayama S, Hamazaki T & Terasawa K (2004) Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. *Eur J Clin Nutr* **58**, 467–473.
208. Bent S, Bertoglio K, Ashwood P *et al.* (2011) A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. *J Autism Dev Disord* **41**, 545–554.
209. Politi P, Cena H, Comelli M *et al.* (2008) Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. *Arch Med Res* **39**, 682–685.
210. Amminger GP, Berger GE, Schäfer MR *et al.* (2007) Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. *Biol Psychiatry* **61**, 551–553.
211. Johnson M, Ostlund S, Fransson G *et al.* (2009) Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. *J Atten Disord* **12**, 394–401.
212. Raz R, Carasso RL & Yehuda S (2009) The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. *J Child Adolesc Psychopharmacol* **19**, 167–177.
213. Voigt RG, Mellon MW, Katusic SK *et al.* (2014) Dietary docosahexaenoic acid supplementation in children with autism. *J Pediatr Gastroenterol Nutr* **58**, 715–722.
214. Mankad D, Dupuis A, Smile S *et al.* (2015) A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. *Mol Autism* **6**, 18.
215. Frensham LJ, Bryan J & Parletta N (2012) Influences of micronutrient and omega-3 fatty acid supplementation on cognition, learning, and behaviour: methodological considerations and implications for children and adolescents in developed societies. *Nutr Rev* **70**, 594–610.
216. Horvath A, Łukasik J & Szajewska H (2017)  $\omega$ -3 Fatty acid supplementation does not affect autism spectrum disorder in children: a systematic review and meta-analysis. *J Nutr* **147**, 367–376.
217. Mazahery H, Stonehouse W, Delshad M *et al.* (2017) Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum disorder: systematic review and meta-analysis of case-control and randomised controlled trials. *Nutrients* **9**, 155.
218. Cooper RE, Tye C, Kuntsi J *et al.* (2016) The effect of omega-3 polyunsaturated fatty acid supplementation on emotional dysregulation, oppositional behaviour and conduct problems in ADHD: a systematic review and meta-analysis. *J Affect Disord* **190**, 474–482.
219. Chang JC, Su KP, Mondelli V *et al.* (2017) Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder (ADHD): A systematic review and meta-analysis of clinical trials and biological studies. *Neuropsychopharmacol* (In the Press).
220. Derbyshire E (2017) Do omega-3/6 fatty acids have a therapeutic role in children and young people with ADHD? *J Lipids* (In the Press).
221. Rudin DO (1981) The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. *Biol Psychiatry* **16**, 837–850.
222. Hibbeln JR (1998) Fish consumption and major depression. *Lancet* **351**, 1213.
223. Su KP, Huang SY, Chiu CC *et al.* (2003) Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. *Eur Neuropsychopharmacol* **13**, 267–271.
224. Marangell LB, Martinez JM, Zboyan HA *et al.* (2003) A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. *Am J Psychiatry* **160**, 996–998.
225. Stoll AL, Severus WE, Freeman MP *et al.* (1999) Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. *Arch Gen Psychiatry* **56**, 407–412.
226. Nemets B, Stahl Z & Belmaker RH (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. *Am J Psychiatry* **159**, 477–479.
227. Mocking RJ, Harmsen I, Assies J *et al.* (2016) Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. *Transl Psychiatry* **6**, e756.
228. Sublette ME, Ellis SP, Geant AL *et al.* (2012) Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. *J Clin Psychiatry* **72**, 1577–1584.
229. Sarris J, Mischoulon D & Schweitzer I (2012) Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. *J Clin Psychiatry* **73**, 81–86.
230. Appleton KM, Sallis HM, Perry R *et al.* (2016)  $\omega$ -3 Fatty acids for major depressive disorder in adults: an abridged Cochrane review. *BMJ Open* **6**, e010172.
231. Peet M, Laugharne J, Rangarajan N *et al.* (1995) Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. *J Psychiatr Res* **29**, 227–232.
232. Yao JK, van Kammen DP & Welker JA (1994) Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. *Schizophr Res* **13**, 217–226.
233. Glen AI, Glen EM, Horrobin DF *et al.* (1994) A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. *Schizophr Res* **12**, 53–61.
234. Edwards R, Peet M, Shay J *et al.* (1998) Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. *J Affect Disord* **48**, 149–155.
235. Hoen WP, Lijmer JG, Duran M *et al.* (2013) Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. *Psychiatry Res* **207**, 1–12.
236. Peet M, Brind J, Ramchand CN *et al.* (2001) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. *Schizophr Res* **49**, 243–251.

237. Peet M & Horrobin DF (2002) A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. *Arch Gen Psychiatry* **59**, 913–919.
238. Fenton WS, Dickerson F, Boronow J *et al.* (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. *Am J Psychiatry* **158**, 2071–2074.
239. Emsley R, Myburgh C, Oosthuizen P *et al.* (2002) Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. *Am J Psychiatry* **159**, 1596–1598.
240. Pawelczyk T, Grancow-Grabka M, Kotlicka-Antczak M *et al.* (2016) A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. *J Psychiatr Res* **73**, 34–44.
241. Joy CB, Mumby-Croft R & Joy LA (2006) Polyunsaturated fatty acid supplementation for schizophrenia. *Cochrane Database Syst Rev* **3**, CD001257.
242. Zanarini MC & Frankenburg FR (2003) N-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. *Am J Psychiatry* **160**, 167–169.
243. Hamazaki T, Sawazaki S, Itomura M *et al.* (1996) The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. *J Clin Invest* **97**, 1129–1133.
244. Hamazaki T, Thienprasert A, Kheovichai K *et al.* (2002) The effect of docosahexaenoic acid on aggression in elderly Thai subjects—a placebo-controlled double-blind study. *Nutr Neurosci* **5**, 37–41.
245. Prasad MR, Lovell MA, Yatin M *et al.* (1998) Regional membrane phospholipid alterations in Alzheimer's disease. *Neurochem Res* **23**, 81–88.
246. Tully AM, Roche HM, Doyle R *et al.* (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. *Brit J Nutr* **89**, 483–489.
247. Cunnane SC, Schneider JA, Tangney C *et al.* (2012) Plasma and brain fatty acid profile in mild cognitive impairment and Alzheimer's disease. *J Alzheimers Dis* **29**, 691–697.
248. Soderberg M, Edlund C, Kristensson K *et al.* (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. *Lipids* **26**, 421–425.
249. Conquer JA, Tierney MC, Zecevic J *et al.* (2000) Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. *Lipids* **35**, 1305–1312.
250. Sinn N, Milte CM, Street SJ *et al.* (2012) Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. *Brit J Nutr* **107**, 1682–1693.
251. Scheltens P, Twisk JW, Blesa R *et al.* (2012) Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. *J Alzheimers Dis* **31**, 225–236.
252. Quinn JF, Raman R, Thomas RG *et al.* (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *J Am Med Assoc* **304**, 1903–1911.
253. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T *et al.* (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegaAD study: a randomized double-blind trial. *Arch Neurol* **63**, 1402–1408.
254. Freund-Levi Y, Basun H, Cederholm T *et al.* (2008) Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. *Int J Geriatr Psychiatry* **23**, 161–169.
255. Kotani S, Sakaguchi E, Warashina S *et al.* (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. *Neurosci Res* **56**, 159–164.
256. Boston PF, Bennett A, Horrobin DF *et al.* (2004) Ethyl-EPA in Alzheimer's disease - a pilot study. *Prostaglandin Leukot Essent Fatty Acids* **71**, 341–346.
257. Phillips MA, Childs CE, Calder PC *et al.* (2015) No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer's disease: a randomised controlled trial. *Int J Mol Sci* **16**, 24600–24613.
258. Sydenham E, Dangour AD & Lim WS (2012) Omega 3 fatty acid for the prevention of cognitive decline and dementia. *Cochrane Database Syst Rev* **6**, CD005379.
259. Zhang XW, Hou WS, Li M *et al.* (2016) Omega-3 fatty acids and risk of cognitive decline in the elderly: a meta-analysis of randomized controlled trials. *Aging Clin Exp Res* **28**, 165–166.
260. Burckhardt M, Herke M, Wustmann T *et al.* (2016) Omega-3 fatty acids for the treatment of dementia. *Cochrane Database Syst Rev* **4**, CD009002.
261. Andrieu S, Guyonnet S, Coley N *et al.* (2017) Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. *Lancet Neurol* **16**, 377–389.
262. Simopoulos AP, Leaf A & Salem N (1999) Essentiality and recommended dietary intakes for omega-6 and omega-3 fatty acids. *Ann Nutr Metab* **43**, 127–130.
263. International Society for the Study of Fatty Acids and Lipids (2004) Recommendations for the intake of polyunsaturated fatty acids in healthy adults (ISSFAL Policy Statement 3). <http://www.issfal.org/news-links/resources/publications/PUFAIntakeReccomdFinalReport.pdf>.
264. French Agency for Food, Environmental and Occupational Health Safety (2003) The omega-3 fatty acids and the cardiovascular system: nutritional benefits and claims. <http://www.afssa.fr/Documents?NUT-Ra-omega3EN.pdf>.
265. National Health and Medical Research Council (2006) Nutrient reference values for Australia and New Zealand including recommended dietary intakes. <http://www.nhmrc.gov.au/publications/synopses/n35syn.htm>.
266. Food and Agricultural Organisation of the United Nations (2010) Fat and Fatty Acids in Human Nutrition: report of an Expert Consultation. Food and Agricultural Organisation of the United Nations, Rome.
267. European Food Safety Authority (2010) Scientific opinion on dietary reference values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids and cholesterol. *EFSA J* **8**, 1461.
268. Mori TA & Woodman RJ (2006) The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. *Curr Opin Clin Nutr Metab Care* **9**, 95–104.
269. Wei MY & Jacobson TA (2011) Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids:



- a systematic review and meta-analysis. *Curr Atheroscler Rep* **13**, 474–483.
270. Schuchardt JP & Hahn A (2013) Bioavailability of long-chain omega-3 fatty acids. *Prostaglandins Leukot Essent Fatty Acids* **89**, 1–8.
271. Ghasemifard S, Turchini GM & Sinclair AJ (2014) Omega-3 long chain fatty acid 'bioavailability': a review of evidence and methodological considerations. *Prog Lipid Res* **56**, 92–108.
272. Raatz SK, Johnson LK & Bukowski MR (2016) Enhanced bioavailability of EPA from emulsified fish oil preparations versus capsular triacylglycerol. *Lipids* **51**, 643–651.
273. Ruiz-Lopez N, Usher S, Sayanova OV *et al.* (2015) Modifying the lipid content and composition of plant seeds: engineering the production of LC-PUFA. *Appl Microbiol Biotechnol* **99**, 143–154.
274. Walker CG, Jebb SA & Calder PC (2013) Stearidonic acid as a supplemental source of  $\omega$ -3 polyunsaturated fatty acids to enhance status for improved human health. *Nutrition* **29**, 363–369.
275. James MJ, Ursin VM & Cleland LG (2003) Metabolism of stearidonic acid in human subjects: comparison with the metabolism of other n-3 fatty acids. *Am J Clin Nutr* **77**, 1140–1145.